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Abstract 
One of the most toxic types of DNA lesions are the DNA double-stranded breaks (DSBs). The 
cells can repair such lesions through several distinct strategies that can be grouped into end-
protection and end-resection based mechanisms. 
Over the past decades, a number of reporter assays have been developed to examine the 
consequences of DNA damage and repair (DDR), mostly focusing on one DSB repair pathway 
at a time. However, a simple reporter that can visualize different DNA DSB repair outcomes 
with high resolution has been missing. Therefore, we developed a fluorescent reporter Color 
Assay Tracing Repair (CAT-R) to assess different DNA DSB repair outcomes by measuring 
the rates of end-protection vs. end-resection-based repair mechanisms. 
I integrated the CAT-R reporter at a single locus in two cell lines and took advantage of the 
highly efficient CRISPR/Cas9 system to mediate a site-specific DSB. I studied the rate of small 
InDels vs. large deletions and found that large deletions occur as frequently as small InDels 
upon Cas9-mediated breaks, consistent with the recent findings. I generated several different 
knock-outs in major genes of the DNA DSB repair and showed that the rate of these repair 
outcomes can be dynamically altered. 
Since I achieved a high resolution of the DSB events that allowed me to measure even minor 
changes in the DSB repair activity, I combined CAT-R with high-throughput flow cytometry 
to screen small pharmacological compounds. I compared 24 drug compounds that are currently 
in clinical trials or used in preclinical studies, targeting key DNA DSB repair enzymes such as 
ATM, DNA-PK, ATR, and PARP as well as a class of inhibitors targeting histone deacetylases. 
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I quantify the levels of enzyme inhibition based on their effects on the associated DNA repair 
pathway and present variances across their in vitro drug potencies of the inhibitor compounds. 
Next, I combined CAT-R with a custom CRISPR/Cas9 arrayed genetic screen targeting 417 
genes involved in DNA damage response (DDR) and evaluated their contribution in DNA DSB 
repair choice. I confirmed the roles of the established players of DSB repair but also revealed 
potentially novel components of DSB repair. In addition, I uncovered how Cas9-mediated DSB 
repair could be modulated to increase the rate of error-free repair, which may have important 
implications for the generation of knock-ins by CRISPR/Cas9. 
Finally, to identify novel PARP1 interactions within the DDR, I applied CAT-R on the custom 
arrayed genetic screen and combined it with PARP inhibition. I uncovered a gene cluster that 
is significantly affected by PARP inhibition regulating a key step during end-resection, 
highlighting potentially new interactions of PARP1 with DDR. Besides, I propose PARP 
inhibition as an alternative approach to increase the chances of a successful knock-in, based 
on my experiments demonstrating that PARP inhibition increases the rates of error-free repair 
to a similar extent with other well-known strategies. 
In summary, in this Ph.D. thesis, I show how CAT-R can be used to assess the functions of 
DNA DSB repair genes and how it can be adapted to genetic and/or chemical screens in a 
variety of cell lines.   
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Zusammenfassung 
Eine der toxischsten Arten von DNA-Läsionen sind die DNA-Doppelstrangbrüche (DSBs). 
Zellen können solche Läsionen durch verschiedene unterschiedliche Strategien reparieren, die 
sich in Mechanismen auf der Basis von Endschutz und Endresektion unterteilen lassen. 
In den letzten Jahrzehnten wurde eine Reihe von Reporter-Assays entwickelt, um die 
Konsequenzen von DNA-Schäden und -Reparaturen (DDR) zu untersuchen. Im Allgemeinen 
ermöglichen diese Reporter die Untersuchung eines einzigen DSB-Reparaturweg. Es fehlte 
jedoch ein einfacher Reporter, der parallel mehrere verschiedene DNA-DSB-
Reparaturergebnisse mit hoher Auflösung visualisieren kann. Aus diesem Grund haben wir 
einen fluoreszierenden Reporter für die Reparatur von Farbassays (Color Assay Tracing 
Repair, CAT-R) entwickelt, um verschiedene DNA-DSB-Reparaturergebnisse durch Messung 
der Endschutzraten im Vergleich zu Reparaturmechanismen auf der Basis von Endresektionen 
zu bewerten. 
Ich habe den CAT-R-Reporter lokusspezifisch in zwei Zelllinien integriert und dann das 
hocheffiziente CRISPR/Cas9-System zur Vermittlung eines positionell klar definierten DSB 
verwendet. Daraufhin habe ich die Rate kleiner InDels im Vergleich zu großen Deletionen 
untersucht und festgestellt, dass, nach Cas9-vermittelten Brüchen, große Deletionen, in 
Übereinstimmung mit der aktuellen Literatur, genauso häufig auftreten wie kleine InDels. Des 
Weiteren habe ich verschiedene Knock-outs in den wichtigsten Genen der DNA-DSB-
Reparatur erzeugt und gezeigt, dass die Rate dieser Reparaturergebnisse dynamisch geändert 
werden kann. 
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Da ich eine hohe Auflösung der DSB-Ereignisse erreichte, die es mir ermöglichte, auch 
geringfügige Änderungen der DSB-Reparaturaktivität zu messen, habe ich CAT-R mit 
Hochdurchsatzdurchflusszytometrie kombiniert, um die Wirkung pharmakologischer 
Verbindungen auf die DNA-DSB-Reparatur zu untersuchen. Ich verglich 24 Wirkstoffe, die 
sich derzeit in klinischen Studien befinden oder in präklinischen Studien verwendet werden, 
um wichtige DNA-DSB-Reparaturenzyme wie ATM, DNA-PK, ATR und PARP sowie eine 
Klasse von Inhibitoren gegen Histondeacetylasen zu untersuchen. Ich habe dann das Ausmaß 
der Enzymhemmung basierend auf ihrer Auswirkung auf den jeweils assoziierten DNA-
Reparaturweg quantifiziert und Unterschiede in der in vitro Arzneimittelpotenz der 
Inhibitorverbindungen detektiert. 
Als nächstes habe ich CAT-R mit einem benutzerdefinierten CRISPR / Cas9-Array-Gen-
Screening kombiniert, das auf 417 Gene abzielte, die an der DNA-Schadensantwort (DDR) 
beteiligt sind, und ihren Beitrag zur Auswahl der DNA-DSB-Reparatur getestet. Ich konnte 
die Rollen der etablierten Akteure der DSB-Reparatur bestätigen, deckte aber auch potenziell 
neuartige Komponenten der DSB-Reparatur auf. Außerdem habe ich herausgefunden, wie die 
Cas9-vermittelte DSB-Reparatur moduliert werden kann, um die Rate fehlerfreier Reparaturen 
zu erhöhen, was wichtige Auswirkungen auf die Erzeugung von Knock-Ins durch CRISPR / 
Cas9 haben kann. 
Um neuartige PARP1-Wechselwirkungen innerhalb der DDR zu identifizieren, habe ich CAT-
R schließlich auf dem benutzerdefinierten Array-Gen-Screen angewendet und mit der PARP-
Hemmung kombiniert. Ich habe einen Gencluster entdeckt, der signifikant von der PARP-
Hemmung beeinflusst wird, die einen Schlüsselschritt während der Endresektion reguliert, und 
dabei potenziell neue Wechselwirkungen von PARP1 mit DDR hervorgehoben. Außerdem 
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schlage ich die PARP-Hemmung als alternativen Ansatz vor, um die Chancen für ein 
erfolgreiches Knock-In zu erhöhen. Dies basiert auf meinen Experimenten, die zeigen, dass 
die PARP-Hemmung die Fehlerfreiheit in ähnlichem Maße erhöht wie andere bekannte 
Strategien. 
Zusammenfassend zeige ich in meiner Dissertation wie CAT-R verwendet werden kann, um 
die Funktionen von DNA-DSB-Reparaturgenen zu bewerten und wie dieses DDR-
Reportersystem an genetische und/oder chemische Screenings in einer Vielzahl von Zelllinien 
angepasst werden kann. 
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Chapter 1 
DNA repair & Cancer 
The study of DNA repair is experiencing a remarkable time of interest with genome integrity 
to be a crucial aspect of cell survival. Some types of cells (cancer cells) can tip the balance of 
the cell cycle by creating a nonstop drive for proliferation. Throughout this process, cancer 
cells ignore or even override cell signals that instruct a naturally occurring DNA damage to 
repair successfully (Jackson and Bartek 2009; Khanna and Jackson 2001; Rich, Allen, and 
Wyllie 2000; Zhou and Elledge 2000). This behavior promotes cancer cell’s mutagenesis, 
aggressiveness, and can even lead to treatment resistance (Curtin 2012; Tubbs and 
Nussenzweig 2017). 
Fortunately, cells have developed specialized DNA repair pathways that can classify into the 
type of DNA damage they repair and collectively are known as the DNA Damage Response 
(DDR) (Lord and Ashworth 2012), and DDR plays a vital role in maintaining genome integrity. 
The investigation of DDR pathways has led to the identification of a complex system 
composing of sensors, transducers, and effectors that ensure the transduction of damage 
signaling, and activation of the appropriate responses such as DNA repair machinery, cell cycle 
arrest and apoptosis (Mondesert et al. 2015). The major DNA repair pathways are base excision 
Introduction: Chapter 1   DNA repair & Cancer  
4 
 
repair (BER), mismatch repair (MMR), nucleotide excision repair (NER), and double-strand 
break (DSB) repair (Sugawara and Nikaido 2014). 
In this Ph.D. study, I developed a novel system to assess the DNA double-strand repair pathway 
choice and evaluate the importance of several DNA repair components after a DSB. 
1.1. Hallmarks of Cancer 
Cancer is a genetic disease that can be caused by the accumulation of mutations in the genome 
that arise through exogenous or endogenous sources like ionizing radiation (IR), genotoxic 
drugs, or such as reactive oxygen species (ROS), and problems encountered during DNA 
replication that trigger replication fork to collapse (Stracker, Usui, and Petrini 2009), (Rich et 
al. 2000). Elevated levels of DNA damage contribute to genomic instability, which is referred 
to as a “Hallmark of Cancer” (Hanahan and Weinberg 2000), (Hanahan and Weinberg 2011).  
1.1.1. Genome instability and double-strand breaks 
One crucial factor contributing to genomic instability is the formation of DNA double-strand 
breaks (DSBs) (Ceccaldi, Rondinelli, and D’Andrea 2016). These lesions are the most serious, 
toxic, and difficult to repair forms of DNA damage since they disrupt the continuity of the 
chromosome (Torgovnick and Schumacher 2015). If these lesions are not repaired correctly, 
they can lead to mutations, deletions, translocations, or genome amplification that scramble 
the encoded information (Costanzo et al. 2009). Therefore the repair of DSBs is fundamental 
to cell survival and uphold of genome integrity (van Gent, Hoeijmakers, and Kanaar 2001), 
(Khanna and Jackson 2001).  
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1.2. DNA double-strand breaks 
The most common kinds of double-strand breaks are caused either due to breaks in replication 
forks when polymerase stall at the site of unrepaired base lesion or due to breaks in both DNA 
strands of the DNA double helix (Shibata et al. 2014a). Cells employ two distinct strategies 
for DNA double-strand break repair: end-resection and end-protection based mechanisms 
(Chiruvella, Liang, and Wilson 2013). The primary representative pathways of the two 
strategies are non-homologous end-joining (NHEJ), and homologous recombination (HR) 
(Bartek 2011; Huertas 2010; Knobel and Marti 2011).  
The pathway choice depends on the cell cycle phase, the complexity of repair, and whether the 
damaged DNA ends are “blunt” (easy to re-join) or “dirty” (not-ligatable). Among others, the 
two pathways differ in their requirement for a homologous template DNA and the fidelity of 
DSB repair (Sugawara and Nikaido 2014). On the one hand, NHEJ is more error-prone (Lieber 
2011), (Sugawara and Nikaido 2014) since it directly ligates the DNA broken ends after a DSB 
by forming small insertions or deletions (InDels). On the other hand, HR remains, in most 
cases, an error-free mechanism (Li and Heyer 2008) with its meticulous template-based 
activity to ensure the highest fidelity of repair. NHEJ is faster and is used more frequent on 
DSBs since it is more available than HR. Consequently, NHEJ is considered to be a source of 
genomic instability (Bunting and Nussenzweig 2013). Besides, NHEJ can operate during any 
cell cycle phase but is most active in G0 and G1 cell cycle phase, just before DNA replication, 
whereas HR activity occurs during S and G2 phases, right after replication (Lord and Ashworth 
2012; Marnef and Legube 2017; Torgovnick and Schumacher 2015; Zhou and Elledge 2000).  
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Collectively, all DNA repair pathways follow five steps of repair: (i) recognition, (ii) 
recruitment, (iii) removal, (iv) reconstruction, and (v) reinstatement with some repair pathways 
to be more active in certain parts of the cell cycle than others (Sugawara and Nikaido 2014), 
(Mondesert et al. 2015). 
1.2.1. Nonhomologous End-Joining 
Nonhomologous end-joining (NHEJ) is one of the DNA repair pathways that the cells are using 
to repair DSBs. The term “non-homologous” refers to the lack of requirement for a DNA 
template, whereas the term classical is often used to highlight the preferred choice among other 
NHEJ pathways (Haber and Moore 1996). In comparison to HR that is restricted to post-DNA 
replication phases of the cell cycle, classical-NHEJ is active throughout the cell cycle and re-
joins DSB ends with minimal processing (Lieber 2011). It does not search for or use a large 
segment of DNA, and the repair proceeds quickly with the potential for loss of nucleotides 
from either side of the DSB junctions or base-pair changes at the breakpoint sequence. 
In simple terms, c-NHEJ initially align and protects the DSB ends, minimally processes the 
damage by removing un-ligatable DNA ends, and fills the break in a fast and potentially 
erroneous way (Lieber 2011; Liu and Huang 2016; Shibata et al. 2014b). 
Data from several studies suggest that classical NHEJ often does a more accurate job than 
initially thought (Davis and Chen 2013; Lieber 2011). Repair of clean breaks usually does not 
result in any information loss of chromosomal rearrangements, but repair of “dirty” breaks can 
result in loss of genetic information (Bétermier, Bertrand, and Lopez 2014). Typically, DSB 
junctions that are repaired by c-NHEJ display evidence of small deletions of 1 - 4 bp at the 
breakpoints. 
Introduction: Chapter 1   DNA repair & Cancer 
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Figure 1: Schematic overview of the pathway choice after a double-strand break. Two distinct repair mechanisms dictate the DSB repair. End-protection 
mechanisms (NHEJ) favor a quick repair with the creation of small InDels, whereas end-resection mechanisms act in multiple ways. After the limited end-resection, 
alt-EJ can process the repair by annealing the broken DNA at microhomologies, creating small InDels. If further resection occurs, then it is possible to anneal the 
broken DNA at homologies that can extend up to 400 bp. This type of repair leads to large fragments of DNA to be lost. Strand invasion will take place if NHEJ does 
not fix the damage in G2. This type of repair requires a template from which an original copy will be used to fix the repair. 
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The eukaryotic Ku70/Ku80 heterodimer (XRCC6, XRCC5) is a damage sensor that initiates 
protection of the double-stranded break (Ferguson et al. 2000), (Difilippantonio et al. 2000), 
(Bunting and Nussenzweig 2013) by forming a ring around the DNA ends recruiting several 
proteins for end-processing (Figure 1). One of them is the DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) that plays a central role in c-NHEJ repair (Chirgadze et al. 2017). 
The actions of DNA-PKcs are setting up the stage for the assembly of the actors in c-NHEJ, 
which include Artemis, XRCC4/DNA ligase IV complex, and XLF (Lieber 2011; O’Driscoll 
and Jeggo 2006; Ochi et al. 2010). Given the importance of DNA-PKcs in c-NHEJ repair, it is 
safe to assume that it also dictates the rate of c-NHEJ acting as a rate-limiting step of the repair 
process. 
The end-processing step of the c-NHEJ repair includes nucleases such as Artemis, a 5’ to 3’ 
endonuclease, which is activated by DNA-PKcs phosphorylation (Moshous et al. 2001). The 
complex that creates a filament to bridge the broken ends is the XRCC4/DNA ligase IV, and 
XLF complex (Figure 1). After the initial end-processing step, the XRCC4/DNA ligase IV 
complex promotes efficient ligation since DNA ligase IV (LIG4) has the necessary plasticity 
to ligate across DNA gaps and re-join incompatible DNA ends  (Grawunder et al. 1997). The 
DNA repair protein NHEJ1 (also known as XLF) also interacts with XRCC4 and increases the 
efficiency of LIG4 DNA ligations (Buck et al. 2006). 
It has been noted that in mammalian cells, the active component of c-NHEJ is highly efficient 
(typical half times of 15 - 30 min) and is responsible for repairing ~ 70% of DSBs (Daley et 
al. 2014; Deriano and Roth 2013). 
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Alternative End-Joining 
Based on the current literature, there are two types of potential end-joining outcomes. One that 
is formed by a direct ligation of DNA ends (c-NHEJ), and another occurs in the absence of 
Ku70/Ku80 dimer, bears small sections of microhomology at the sites close to DSB (Roth, 
Porter, and Wilson 1985), (Roth and Wilson 1986), (Boulton and Jackson 1996a), (Boulton 
and Jackson 1996b). In the literature, the emergence of three different names assigned to 
alternative EJ repair has been used interchangeably: backup NHEJ, microhomology-mediated 
end-joining (MMEJ), and noncanonical NHEJ. Throughout this Ph.D. thesis, the name 
alternative end-joining (alt-EJ) is used, which reflects its independence for c-NHEJ (Dueva 
and Iliakis 2013; Frit et al. 2014). 
Previous studies have reported that alt-EJ may actively compete with both c-NHEJ and HR 
repair. Biochemical data (Wang et al. 2003), (Daley and Wilson 2005) show that DSBs can be 
repaired independently of the Ku-mediated c-NHEJ repair mechanism and instead require an 
alternative end-joining (alt-EJ) pathway that uses 6 to 8 bp of microhomology as an 
intermediate step (Bunting and Nussenzweig 2013), (Gomez-Cabello et al. 2013). Studies 
show that DNA resection, which is a prerequisite for the microhomology intermediate step, 
only happens in the S and G2 phase and it is inhibited by Ku70/Ku80 heterodimers (Liu and 
Huang 2016).  
The first responders to alt-EJ repair are poly [ADP-ribose] polymerase 1 (PARP1) and p53-
binding protein 1 (53BP1) (Figure 1). However, the DSB repair protein MRE11 and the DNA 
endonuclease RBBP8 (CtIP) are also implicated in the initial end-resection step (Mojumdar et 
al. 2019; Stracker and Petrini 2011). Recent studies identified DNA polymerase Q (POLQ) as 
a possible player in alt-EJ (Malaby et al. 2017) with DNA ligase I (LIG1) or DNA ligase III 
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(LIG3) to perform the final DNA ligation step (Pace et al. 2010). The LIG3 cofactor, XRCC1, 
is also implicated in alt-EJ (Bunting et al. 2012). However, the exact mechanism of repair is 
still unknown, with several players of alt-EJ to be missing (Figure 1).  
Evidence suggests that c-NHEJ causes a low rate of translocations, but when absent, alt-EJ 
becomes active and produces an increased number of chromosome rearrangements (Howard 
H.Y. Chang et al. 2017). Therefore alt-EJ is of particular interest in research since its 
microhomology signatures are reported at the breakpoints of chromosomal rearrangements in 
human cancer cells (McVey and Lee 2008), (Tsai et al. 2008), (Bunting and Nussenzweig 
2013). There are some features that characterize the alt-EJ pathway. Initially, the DNA repair 
results in higher rates of deletions, with or without signs of neighboring microhomology 
sequence. Consequently, lower rates of fidelity are anticipated.  
1.2.2. Homologous Recombination  
Upon DNA double-strand breaks, homologous recombination repair (HR) mediates accurate 
repair, protects the genome from chromosomal rearrangements or gross chromosomal loss, and 
cell death in a complicated template-directed repair (Figure 1). HR factors contribute to the 
protection and duplication of the genome fundamentally with mutations in HR gene, to have 
been linked to carcinogenesis (Bunting and Nussenzweig 2013; Li and Heyer 2008; Shibata et 
al. 2014a). 
HR matches the break ends to an intact DNA molecule of identical or near-identical DNA 
sequences. The pathway can be broken down into four stages: (1) DNA end resection, (2) 
RAD51 filament formation on the newly created single-stranded DNA overhang, (3) RAD51 
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dependent strand exchange between the broken DNA and the intact sequence donor, (4) DNA 
repair synthesis and resolution of the joint molecule repair intermediate. 
The first step of HR is the activation of checkpoint kinases by the MRE11-RAD50-NBS1 
(MRN) complex. This action arrests the cell cycle and simultaneously recruits additional DNA 
repair proteins at the DSB end. During the initial end-resection, MRN generates a single-
stranded DNA (ssDNA) that is important for initiating homologous recombination (Figure 1). 
This step commits the DNA repair to HR and simultaneously prevents NHEJ from interfering. 
Together, those steps of creating small overhangs are called “presynapsis” (Ceccaldi et al. 
2016; Gudmundsdottir and Ashworth 2006; Shibata et al. 2014a). The occurring ssDNA 
extends way past the original DSB point with replication protein A (RPA1) molecules to coat 
and protect the exposed stretch of DNA.  
The above step is a crucial feature for enabling Rad51 filament to attach to the ssDNA’s 3’ end 
and to search for an area of homology on the sister chromatid (Figure 1). Once Rad51 
identifies an area of homology, it attacks the homologous sequence and transfers part of its 
DNA strand. Rad51 pulls part of the DNA strand and creates a DNA heteroduplex (D-loop). 
During this process, Rad51 superintendents the exchange and pairing of the homologous DNA 
sequence with the sister chromatid. Several proteins are involved in protecting the broken DNA 
ends from nuclease activity, enabling the strand invasion and filament migration, and guarantee 
the synthesis of more than 50 newly synthesized nucleotides (Figure 1). 
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1.2.3. Single-Strand Annealing 
Single-strand annealing (SSA) is a DNA repair process that initiates when a double-strand 
break occurs among two repeated sequences (Bhargava, Onyango, and Stark 2016; Raphael, 
Beatrice, and D’Andrea 2016). Single-stranded regions are created adjacent to the DNA break 
(Figure 1). If they extend until the repeated sequences, then the complementary strands can 
anneal to each other. This annealed intermediate can be processed by digesting the single-
stranded tails and filling in the gaps. The smallest homology reported is at 29 bp, but it can 
reach much more than hundreds of bps (Bennardo et al. 2008; Ceccaldi et al. 2016; Howard H. 
Y. Chang et al. 2017). 
The DNA repair protein Rad52 is required for recombination processes, including SSA 
(Figure 1). It possesses the ability to bind to the 3’ ends of DNA (Sugawara et al. 2002). Rad59 
is a homolog of Rad52, and it is also required for SSA since it possesses the same DNA binding 
properties and strand annealing activity as Rad52 (Chakraborty et al. 2016; George and Alani 
2012). RPA is another DNA binding factor implicated at SSA. The RPA complex is required 
to coat the single-stranded DNA ends. Interestingly, Rad51 is not required for SSA since it is 
involved in strand invasion and hence is not expected to play a role in SSA, where two strands 
interact by intertwining around each other (Howard H. Y. Chang et al. 2017; Mansour et al. 
2008).  
The mismatch repair proteins MSH2 and MSH3 are also required for efficient SSA. They 
remove the non-homologous 3' tails from the annealed intermediate during the repair process 
(Eichmiller et al. 2018). MSH2 and MSH3 complex has a strong preference for recognizing 
"loop-out" structures such as those formed by frameshift replication errors. Possibly MSH2 
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and MSH3 bind to the branched junction between the single and double-stranded DNA 
(Sugawara et al. 2002, 2004). The complex stabilizes the annealed intermediate and signals the 
endonuclease to cleave the single-stranded tail. MSH2 and MSH3 may act to stabilize junction 
where the repeat sequences are small, e.g., 0.2 kb (Bennardo et al. 2009; George and Alani 
2012). 
1.2.4. The battle between end-protection and end-resection 
Previous studies have reported that the first responder to a DSB is the damage sensor complex 
MRN familiar to both HR and NHEJ (Shibata et al. 2014a). Its configuration appears to 
influence the pathway choice. Resection of the 5’ DNA strand is a requirement and a definitive 
commitment to DNA double-strand break repair by HR (Dimitrova and de Lange 2009; Gu, 
Lin, and Hong 2017; Liu and Huang 2016; Shibata et al. 2014b). On the other hand, NHEJ 
factor Ku70/Ku80 binds and protects DNA ends to favor for a quick DNA re-ligation (Figure 
2). The balance between p53-binding protein 1 (53BP1) and breast cancer type 1 susceptibility 
protein (BRCA1) mediates the extent of end-resection since BRCA1 antagonizes 53BP1 to 
promote resection in the S and G2 cell cycle phase (Escribano-Díaz et al. 2013; Grabarz et al. 
2013; Liu and Huang 2016; Zhang and Jasin 2011). MRE11 and retinoblastoma-binding 
protein 8 (RBBP8, also known as CtIP) mediate the initial limited end-resection step (end 
clipping) and typically results in resection of 20 bp or less. This short resection tips the balance 
of DNA double-strand break repair pathway choice from NHEJ in G1 towards HR in S and G2 
phase of the cell cycle. At a time when the newly synthesized sister chromatid can act as a 
homologous repair template. The second, more extensive phase of end-resection (Figure 2), is 
mediated by exonuclease 1 (EXO1), BLM RecQ like helicase (BLM), DNA replication 
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Helicase/Nuclease 2 (DNA2), and WRN RecQ like helicase (WRN) that definitely commits 
the choice to HR or SSA, but not to alternative end-joining repair (Liu and Huang 2016; 
Shibata et al. 2014b; Wang et al. 2015). What is not yet clear is the connection between other 
components or even pathways of the DDR that can modify the DSB repair choice. 
 
Figure 2: The battle between End-protection and End-resection. Schematic illustration of the immediate steps 
after the induction of a double-strand break (DSB). 53BP1 and RIF1 stabilize the broken ends to favor a fast ligation 
initiated by Ku70/Ku80 dimer. BRCA1 and CtIP are antagonizing 53BP1 and RIF1 to enable end-resection. 
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Chapter 2 
Clinical inhibitors: Targeting DNA repair 
2.1. Small pharmacological compounds 
The use of specific DNA repair inhibitors targeting prominent DNA repair kinases in cancer 
treatment is rapidly expanding as a therapeutic strategy. Therefore, the development of 
additional small pharmacological compounds is rapidly moving through the preclinical 
developmental pipeline. Several studies describe the selectivity, efficacy, and cytotoxicity of 
various inhibitors in vitro or in vivo. There are a handful of DDR inhibitors and they typically 
require a different type of in vitro test to evaluate their level of engagement in the choice of 
DNA repair.  
In this Ph.D. study, I performed experiments to compare several different compounds with the 
same in vitro DNA repair assay. I present interesting differences within compounds of the same 
class and address specific aspects of pharmacodynamics that can explain how the inhibitors 
can tip the balance of DNA repair choice.  
Introduction: Chapter 2   Clinical inhibitors: Targeting DNA repair  
16 
 
2.1.1. Targeting end-protection with DNA-PKcs inhibitors 
DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) has a pivotal role in c-NHEJ 
and the regulation of DNA damage response. In humans, it is encoded by the gene designated 
as PRKDC. It is a DNA-activated serine/threonine-protein kinase, abundantly expressed in 
almost all mammalian cells, and it functions as the catalytic subunit of the DNA-PK 
holoenzyme (Dungl, Maginn, and Stronach 2015). DNA-PKcs belongs to the 
phosphatidylinositol-3-OH kinase (PI(3)K)-related protein (PIKK) superfamily (Jiang et al. 
2015). It is a colossal single-chain protein of 4128 amino acids (Moshous et al. 2001). 
During the NHEJ process, DNA-PKcs interacts with Ku70/Ku80 heterodimers regulating a 
series of complex events: (1) the synapsis, (2) end-processing and (3) ligation (Lieber 2011). 
The Ku70/Ku80 dimer has a ring-like structure that binds first to the DNA break encircling the 
DNA end and allows the dimer to translocate along the duplex (Walker, Corpina, and Goldberg 
2001). DNA-PKcs is recruited through interaction with the Ku80 C-terminus (Alt et al. 1992; 
Gell and Jackson 1999) and two DNA-PKcs complexes are required to hold the DNA ends 
close together (Chirgadze et al. 2017). The DNA-PKcs kinase is activated once associated with 
the Ku70/Ku80 dimer and the DNA terminus. Besides, DNA-PKcs can auto-phosphorylate, 
enabling a conformational change that releases the DNA ends and makes them available to 
other factors, including NHEJ components involved in DNA end-processing and ligation steps. 
DNA-PKcs kinases allow the DNA DSB to be repaired promptly when a sister chromatid is 
unavailable, a process that is also used in V(D)J recombination (Alt et al. 1992). As such, 
DNA-PKcs act as a “doorkeeper” that protects DNA ends from initial processing and ligation, 
until the two broken ends are correctly positioned (Costantini et al. 2007; Dip and Naegeli 
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2005; Jette and Lees-Miller 2015; Um et al. 2003). End-processing of complex DSBs requires 
trans-phosphorylation of DNA-PKcs by ATM serine/threonine kinase. This activation serves 
to recruit Artemis endonuclease to the site of DNA damage. DNA-PKcs phosphorylation may 
also affect DSB repair pathway choice since it has been shown that cells deficient in DNA-
PKcs demonstrate increased levels of HR-mediated repair of DSBs (van Oorschot et al. 2016). 
The activity of DNA-PKcs kinase can also be stimulated by poly (ADP-ribose) polymerase 
(PARP), independently of the Ku70/Ku80 complex suggesting that PARP, in addition to its 
crucial role in BER, may additionally facilitate DNA DSB repair via inhibitory regulation of 
DNA-PKcs (Ruscetti et al. 1998).  
DNA-PKcs is an attractive therapeutic target for cancer. In 1994, Lilly Pharmaceuticals 
reported the compound LY294002 as an inhibitor of PI3K (Velic et al. 2015). Despite 
LY294002 side-effects (in vivo cytotoxicity), its structure paved the way for the development 
of more potent and selective DNA-PKcs ligands with improved physicochemical properties like 
the KU-0060648 and M3814 compounds (Harnor, Brennan, and Cano 2017). DNA-PKcs 
inhibitors are tested clinically in solid tumors and hematological malignancies both as a 
monotherapy and combination with chemotherapy or radiotherapy (Klein et al. 2017). For 
instance, radiation therapy becomes one of the significant ancillary methods of liver cancer 
therapy (Pascale et al. 2016). Liver cancer cells repair their damaged DNA predominantly by 
non-homologous end-joining (Yang et al. 2016). Upon DNA-PKcs inhibition, those cells with 
simultaneous administration of ionizing irradiation result in unresolved double-strand breaks 
in the genomic DNA of the target cells that lead to tumor cell death (Dolman et al. 2015). 
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2.1.2. Targeting ATM-CHK2 axis as a therapeutic target in cancer 
As discussed earlier, the protection of the genome by DNA repair factors is rooted in a broader 
cellular response known as the DNA damage response. The ataxia-telangiectasia mutated 
serine-threonine kinase (ATM) signaling pathway is well conserved and is central to the 
maintenance of genome integrity (Awasthi, Foiani, and Kumar 2016). ATM kinase belongs to 
the phosphoinositide 3-kinase (PI3K)-related kinase (PIKK) family along with DNA-PKcs and 
it phosphorylates proteins containing Ser or Thr residues that are followed by Gln (Bakkenist 
and Kastan 2004). ATM triggers a phosphorylation cascade that sets in motion a series of post-
translational protein modifications that in the majority of the cases upregulate the cell cycle 
checkpoint pathways (Bakr et al. 2015; Batenburg et al. 2017; Geuting, Reul, and Löbrich 
2013; Muraki et al. 2013). Once the DNA damage is induced, the ATM-CHK2 (checkpoint 
kinase 2) axis controls the G2/M checkpoint by delaying mitosis and allows cells to avoid the 
toxic levels of genome instability. In addition, ATM plays a part in the local response to DNA 
DSB (Figure 3 A). Even though ATM is the master kinase of the DNA damage response, it is 
not the first protein to arrive at a DNA double-strand break. As previously described, the MRN 
complex rapidly binds to the chromosomal breaks and acts as the primary sensor. Among other 
targets, ATM phosphorylates the histone variant H2AX which is also phosphorylated by DNA-
PKcs (Dimitrova and de Lange 2009; Geuting et al. 2013; Mansour et al. 2008; Rybanska-
Spaeder et al. 2013).  
ATM has long been considered as a potential drug target for cancer therapy since it is a 
facilitator of DNA damage response and is considered as a tumor suppressor (Kandoth et al. 
2013). However, the generation of specific inhibitors for ATM is a difficult mission. The initial 
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compounds that have been used to inhibit ATM were pan-PI3K inhibitors like LY294002, 
caffeine, and wortmannin (Sarkaria et al. 1998, 1999). More specific ATM inhibitors have 
been developed over the years such as KU-55933, KU-60019, and KU-559403 (Batey et al. 
2013; Fokas et al. 2012; Guo et al. 2014; Toledo et al. 2011). Recent evidence shows promising 
results that inhibition of ATM can sensitize cells to ionizing radiation (Klein et al. 2017; Ronco 
et al. 2017), therefore efforts to develop potent and selective compounds are still ongoing. 
  
Figure 3: The ATM and ATR cell signaling axis. Schematic overview of the (A) ATM-CHK2, and (B) ATR-CHK1 
axis. Illustration adapted from (Feehan and Shantz 2016), (Zhao et al. 2018). 
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2.1.3. Targeting ATR-CHK1 axis as a therapeutic target in cancer 
Further vital components of the DDR are the ATM and Rad3-related serine-threonine kinase 
(ATR) and checkpoint kinase 1 (CHK1) (Rundle et al. 2017) that link DNA lesions to cell 
cycle checkpoint and repair. These protein kinases play a critical role since knock-out of ATR 
or CHK1 is lethal in early embryonic life (Brown and Baltimore 2000; Takai et al. 2000). The 
presence of single-stranded DNA (ssDNA) activates ATR and typically, ssDNA arises from 
stalled replication forks, nucleotide excision repair (NER) intermediates or resected DSBs that 
have been subject to exonuclease digestion. Therefore, ATR is suggested to play a role in both 
DNA damage repair and cell cycle checkpoint regulation. Besides, ATR kinase is as well a 
member of the PIKK family, exhibiting a similar structure to ATM and DNA-PKcs. The 
primary phosphorylation target of ATR is CHK1 (Figure 3 B). Both ATR and CHK1 are 
responsible for transducing the signal to reduce replication stress and indicate single-strand 
DNA. Both are closely linked to DNA repair by regulating end-resection pathways. Early 
studies have shown that ATR-CHK1 signaling pathway phosphorylates and activates the 
critical homologous recombination repair (HR) regulatory protein BRCA1 (Tibbetts et al. 
2000) and protects cells from 5-fluorouracil cytotoxicity (Fujinaka et al. 2012). Furthermore, 
it is reported that the depletion of ATR reduces the efficiency of HR in a DNA DSB repair 
reporter assay (Bakr et al. 2015; Fujinaka et al. 2012).  
The functions of the S phase checkpoint proteins ATR, CHK1, and WEE1 become critically 
important in cancer with loss of G1 cell cycle checkpoint control. Those proteins ensure that 
significant time is provided to deal with replication problems and that the appropriate pathways 
of replication fork recovery are activated, avoiding premature mitosis. This results in the S and 
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G2 checkpoints dependency by the cells, a strategy that may be exploited by inhibiting the 
ATR, CHK1 and WEE1 kinases in cancer cells. Even if the early ATR and CHK1 inhibitors, 
such as UCN-01, were not specific enough (Senderowicz 2000), the most recently developed 
inhibitors exhibit greater potency and higher selectivity against its prospective targets, with 
new ATR inhibitors (AZD6738, M6620) to enhance tumor cell killing (Jin et al. 2018; Sarkaria 
et al. 1999).  
Wee1 is an essential target of CHK1 acting as an inhibitor of CDK1 and takes part in the ATR-
CHK1 pathway in multiple ways. A selective small-molecule inhibitor of WEE1 (MK-1775, 
now known as the AZD1775; IC50= 5 nM) has been identified from a high-throughput screen 
based on an in vitro kinase assay (Garcia et al. 2017; Jin et al. 2018). The AZD1775 inhibitor 
causes G2/M checkpoint release after DNA damage, and it has demonstrated increased 
cytotoxicity in combination with specific chemotherapeutic drugs such as gemcitabine, 
platinum compounds, and topotecan in p53-deficient cells. Besides, it has shown antitumor 
efficacy in xenograft models and patient-derived tumor explants ex vivo (Hirai et al. 2009), (H. 
Kim et al. 2016). It has been reported that the AZD1775 compound inhibits WEE1, proto-
oncogene tyrosine-protein kinase (YES1), protein kinase membrane-associated 
Tyrosine/Threonine 1 (PKMYT1) kinases as well as polo-like kinase1 (PLK1) with similar 
potency as the intended target WEE1 itself (Hirai et al. 2009; Wright et al. 2017). WEE1 kinase 
has been used for targeted molecular therapy of gastric cancer (H. Kim et al. 2016). The small-
molecule inhibitor of WEE1, AZD1775 synergizes with a PARP inhibitor (Olaparib) by 
impairing HR and enhancing DNA damage and apoptosis in acute myeloid leukemia (AML) 
(Garcia et al. 2017). 
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2.1.4. HDAC inhibitors in cancer development and therapy 
Epigenetic abnormalities have been linked with some classical “Hallmarks of Cancer” 
underlying a close connection between genetic and epigenetic mechanisms during the 
development of cancer (Li and Seto 2016), (Flavahan, Gaskell, and Bernstein 2017). 
Epigenetic mechanisms are implicated in critical steps of cancer such as tumor suppressor 
silencing or oncogene activation by repurposed enhancers or even cell fate transitions.  
Histone acetylation is a process that is controlled by histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). HDACs remove acetyl group and can alter transcription of 
oncogenes and tumor suppressor genes. In addition, HDACs deacetylate numerous nonhistone 
cellular substrates that govern a wide array of biological processes (Li and Seto 2016). Several 
studies implicate histone deacetylases (HDAC) during modulating the acetylation status of 
histone and nonhistone proteins (Barneda-Zahonero and Parra 2012; Chun 2015; Yang and 
Seto 2007). Post-translational modification of histones and non-histone proteins modulate gene 
transcription, chromatin remodeling, and nuclear architecture which are involved in the 
regulation of cell cycle, apoptosis, DDR, metastasis, angiogenesis, autophagy, and other 
cellular processes (Li and Zhu 2014), (Li and Seto 2016). There are 18 potential human 
HDACs grouped into four classes (class I, II, III, IV), with most of them to be involved in 
several different stages of cancer. 
More specifically, HDAC1 and HDAC2 are recruited to DNA-damage sites to deacetylate 
histones H3K56 and H4K16, and to facilitate nonhomologous end-joining (c-NHEJ) (Miller et 
al. 2010). This behavior suggests a direct role for these two enzymes during DNA replication 
and double-strand break (DSB) repair. Moreover, HDAC3 is associated with DNA-damage 
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control, even if it is not localized to DSB DNA-damage sites. Besides, it is shown that class I 
HDACs can regulate other proteins that are involved in the DNA-damage response as well; 
including ATM, ATR, and BRCA1 (Thurn et al. 2013). Also, HDAC9 and HDAC10 are 
reported to be required for homologous recombination (HR) (Li and Seto 2016). 
To date, numerous synthetic or natural molecules that target classes I, II, and IV enzymes have 
been developed and characterized, although interest in the class III family is increasing. 
Currently there are numerous HDACi under clinical development, which can be divided into 
three groups based on their specificity: (1) the nonselective HDACi, such as Vorinostat and 
Panobinostat; (2) the selective HDACi such as class I HDACi (Entinostat) and (3) the multi-
pharmacological HDACi (Li and Seto 2016).  
Vorinostat (SAHA) was the first HDACi to be approved by the FDA to treat cutaneous T-cell 
lymphoma (CTCL) in 2006. Since then, three more HDACi (Romidepsin, Belinostat, 
Panobinostat) have been approved for the treatment of different cancer types such as CTCL, 
peripheral T-cell lymphoma (PTCL) and multiple myeloma (MM) respectively (Li and Seto 
2016). 
Histone deacetylase (HDAC) inhibitors have shown to sensitize breast and ovarian cancer cell 
lines to PARP inhibition and cisplatin, in part via depletion of BRCA1 (Thurn et al. 2013). As 
the induction of BRCAness through BRCA1 downregulation mediated by HDAC, pan-HDAC 
inhibitors have been shown to cause transcriptional downregulation of RAD51 (House, Koch, 
and Freudenreich 2014). Current evidence suggests that HDAC inhibitors have a rather 
pleiotropic effect on HR genes and other cellular pathways (Chen et al. 2017). HDAC 
inhibitors decrease the protein levels of several HR factors, such as BRCA1 and BRCA2, 
RAD51 (Stengel and Hiebert 2015). 
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2.1.5. PARP inhibitors: Synthetic lethality in the clinic 
The nuclear enzyme poly(ADP-ribose) polymerase (PARP-1) is an essential target in cancer 
therapy, and it is acknowledged that inhibiting PARP in patients could also have therapeutic 
potential in the treatment of many other diseases (Ray Chaudhuri and Nussenzweig 2017).  
PARP is a superfamily of proteins localized in the nuclei. So far, three members of this family 
have been recognized to have a role in DNA repair, with PARP1 leading that activity. PARP1 
is also known as a molecular nick-sensor, and it is part of the enzymatic machinery of the BER 
pathway (Wood and Doublié 2016). PARP1’s role is to sense SSBs, assess the extent of their 
damage, decide whether the damage can or should be repaired, and approve the repair or trigger 
apoptosis (Figure 4). PARP1 “flags” the damaged DNA by binding to the damaged site. Then 
it undergoes a conformational change, which recruits proteins to relax the chromatin, scaffold 
the damage, and repair the site (Bourton et al. 2017; Brown et al. 2017; Forst et al. 2013; Gu 
et al. 2017). PARP is inactive until bound to a DNA strand break. This binding activates the 
enzyme creating a negatively charged target at the SSB which recruits the enzymes required 
to form the BER multiprotein complex. This complex is made up of XRCC1, LIG3, and the 
DNA polymerase POLβ (Wood and Doublié 2016).  
Briefly, PARP inhibition stalls BER machinery, which causes unrepaired SSBs to accumulate 
(Figure 4). Typically, BER machinery repairs this type of DNA damage, but if PARP is 
inhibited the DNA repair process is channeled to the DSB repair pathways. PARP1/2 activates 
XRCC1 in the HR pathway and is involved in a regulatory feedback loop with BRCA1. 
Simultaneously, PARP1/2 seems to inhibit the NHEJ pathway by inactivating DNA-PKcs and 
the activity of ATM’s checkpoint. Although PARP’s overall contribution to the canonical 
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NHEJ pathway is still uncertain, collectively, PARP’s actions can affect which DSB repair 
pathway is selected (Brenner et al. 2011; Bryant and Helleday 2006).  
 
Figure 4: A model describing the PARP catalytic cycle. Schematic overview of PARP processing. Step (1) 
illustrates the non-DNA bound state of PARP1. It exists in a relatively disordered conformation, commonly referred 
to as “beads on a string”. PARP1 structure entails three zinc finger–related domains (ZnF 1, 2, and 3): the BRCA1 
C-terminus domain (BRCT); the tryptophan-, glycine-, arginine-rich domain (WGR); and the catalytic domain, which 
encompasses two subdomains; a helical domain (HD) and an ADP-ribosyltransferase (ART) catalytic domain. In 
this non-DNA bound state, HD acts as an autoinhibitory domain preventing binding of the PARP-superfamily 
cofactor, β-NAD+, to its ART binding site. (2) Damage of the DNA double helix often causes the formation of SSBs 
that change the normal orientation of the double helix and provides a binding site for DNA binding PARP1 ZnF 
domains (3). The interaction of ZnF 1, 2, and 3 with DNA initiates a stepwise assembly of the remaining PARP1 
protein domains onto the PARP1/DNA nucleoprotein structure (4). During this process leads to a change in HD 
conformation results in the loss of its autoinhibitory function, thus allosterically activating PARP1 catalytic activity. 
In step (6) the ART catalytic activity drives the PARylation of PARP1 substrate proteins, mediating the recruitment 
of DNA repair effectors, chromatin remodeling, and eventually DNA repair. In step (7) PARP1 auto-PARylation 
causes the release of PARP1 from DNA and the restoration of a catalytically inactive state. In step 5, PARP is 
trapped on DNA and blocks the replication fork to progress and requires HRR for repair. Several clinical PARPi, 
each of which binds the catalytic site, prevent the release of PARP1 from DNA, “trapping” PARP1 at the site of 
damage, potentially removing PARP1 from its normal catalytic cycle. Figure adapted from (Lord and Ashworth 
2017). 
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Cells that are missing both alleles of BRCA1 or BRCA2 have no HR functionality, which 
leaves repairs in the hands of NHEJ. Its limited ability to repair extensive DSB damage leads 
to cell death. Poly ADP-ribose polymerase (PARP) inhibitors are the first clinically approved 
drugs that exploit the concept of synthetic lethality (Hengel, Spies, and Spies 2017; 
Konstantinopoulos et al. 2015; Minchom, Aversa, and Lopez 2018). Almost 40 years ago, it 
was shown that small nicotinamide analogs inhibit PARylation and enhance the cytotoxicity 
of dimethyl sulfate, a DNA damaging agent (Durkacz et al. 1980; Purnell and Whish 1980; 
Terada et al. 1979). Subsequent efforts to the development of clinical PARP inhibitors led to 
the first generation of compounds, such as Rucaparib (Pfizer/Clovis), Niraparib (Merck & 
Co./Tesaro), Olaparib (KuDOS Ltd/AstraZeneca plc.), and Veliparib (Abbvie) (Lord and 
Ashworth 2017). A second more potent generation of PARP inhibitors was developed recently, 
Talazoparib (Lead/Biomarin/Medication/Pfizer) (Hopkins et al. 2015).   
 
Figure 5: Clinical PARP inhibitors. Structures of seven clinical PARP inhibitors are shown. The ability of each 
PARPi to trap PARP1 on DNA differs and broadly correlates with cytotoxic potency. The nicotinamide moiety 
common to PARPi is shown in red. The blue arrows indicated the racemic centers for Talazoparib, explaining the 
selectivity of the active enantiomer. Figure adapted from (Pommier, O’Connor, and De Bono 2016). 
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All PARP inhibitors interact with the binding site of the PARP enzyme cofactor, β 
nicotinamide adenine dinucleotide (β-NAD+), in the catalytic domain of PARP1 and PARP2 
(Figure 5). However, clinically used PARP inhibitors have different abilities to trap PARP1/2 
on DNA. It has been shown that a group of compounds that are among the first developed 
PARP inhibitors (INO-1001, Iniparib, Veliparib) do not possess any PARP trapping activity 
and therefore they are no longer considered potent PARP inhibitors (Lord and Ashworth 2017). 
Overall, PARP inhibition shows promising results in clinical studies as monotherapy for 
cancers with homologous recombination defects (Aly and Ganesan 2011; Carney et al. 2018; 
Minchom et al. 2018).  
 
 28 
 
Introduction: Chapter 3   Genome engineering and DNA repair assays 
29 
 
 
Chapter 3 
Genome engineering and DNA repair assays 
3.1. Genome engineering 
Since the 1970s, genome engineering is used as a method to insert (or remove) genetic elements 
into organisms. It uses engineered nucleases to target specific DNA sequences generating a 
double-strand break (DSB) or guide effector molecules to DNA locations, in a precise and site-
specific manner. For modifying the DNA sequence, a DSB needs to occur so that the cell’s 
endogenous repair mechanism can be activated and once manipulated can result in the desired 
sequence change (Doudna and Charpentier 2014). This methodology allows scientists to 
disrupt or modify genes with extraordinary precision and has been implemented for several 
years.  
In the late 1950s, Rich and colleagues described the idea of a triple helix formation (RICH 
1958; Varshavsky 2006), that inspired the early approaches of gene editing. Typically, 
oligonucleotides coupled to chemical cleavage or cross-linking reagents like bleomycin or 
psoralen were used to induce site-specific modifications (Faruqi, Egholm, and Glazer 1998; 
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Sandor and Bredberg 1995; Strobel et al. 1991; Strobel and Dervan 1990). Other methods used 
peptide nucleic acids or polyamides to enable targeted binding to chromosomal loci (Cho, 
Parks, and Dervan 1995; Faruqi et al. 1998; Gottesfeld et al. 1997). Another strategy was to 
use self-splicing introns to change sequences at the DNA or RNA level (Sullenger and Cech 
1994; Yang et al. 1996; Zimmerly et al. 1995). All these approaches demonstrated the 
effectiveness of base pairing for site-specific genome modification. However, none of them 
was able to lead to robust methods.  
Over the following years, homing endonucleases were emerged that were capable of site-
specific DNA cleavage and allow the integration of a desired exogenous sequence (Chevalier 
et al. 2002; Jacquier and Dujon 1985; Pavletich and Pabo 1991). This stimulated the creation 
of modular DNA recognition proteins that could function as site-specific nucleases when 
coupled to the sequence-independent nuclease domain of the restriction enzyme FokI 
(Bibikova, M., Beumer, K., Trautman, J.K., Carroll 2003; Boch et al. 2009; Frank, Skryabin, 
and Greber 2013; Moscou and Bogdanove 2009). Nowadays, two main groups of enzymes are 
used to introduce the DSBs, the FokI, and the Cas9 enzymes (Ran et al. 2013).  
The FokI is a DNA-cutting enzyme derived from the bacterium Flavobacterium okeanokoites, 
and it is fused with proteins to create programmable endonucleases such as zinc-finger 
nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). The first-
generation genome editing tool (ZFN) and later the next-generation genome editing tool 
(TALENs) that offered precision and control lead the way for functional studies in the era of 
genome engineering (Kim and Kim 2014; Ramirez et al. 2012; Zhang et al. 2014). However, 
these approaches required the generation of custom-tailored proteins for each targeting event, 
limiting their range of use on both practicality and cost.  
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Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 is the most recent 
addition to the arsenal of genome engineering tools that a scientist can use. It is an RNA-
mediated adaptive immune system found in several species of bacteria and archaea, and 
functions to protect host cells from invasion by foreign DNA elements (Sontheimer and 
Barrangou 2015). CRISPR technology enables scientists to target the genome accurately, for 
a variety of purposes, generally either cutting the DNA to induce changes in the DNA 
sequences or to precisely deliver molecules, for example, effector or visualization molecules, 
to the sites of DNA. 
3.2. The CRISPR toolkit 
The introduction of the CRISPR/Cas9 system offered an unprecedented opportunity to the 
researcher’s toolkit in designing experiments with the scope of determining the role of genes 
at the cellular level mechanistically (Jinek et al. 2013; Mukherjee-Clavin, Tomishima, and Lee 
2013). Although still not trivial, this technology provides an opportunity to understand the 
genetic basis of complex diseases like cancer.  
In this Ph.D. thesis, we are using CRISPR/Cas9 among other tools like TALENs, ZFN or 
meganucleases (e.g., I-SceI) because it provides efficiency, flexibility and cost-effectiveness 
to work in a high-throughput manner across different cell lines (Belhaj et al. 2013), (Sternberg 
et al. 2015).  
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3.1.1. CRISPR/Cas9 system 
Cas9 is an RNA-guided endonuclease whose mechanism was clarified in 2012 (Doudna and 
Charpentier 2014), (Ran et al. 2013). It induces a targeted double-strand DNA break with the 
help of a small ~ 20 nucleotide RNA sequence termed the ‘guide RNA’ (gRNA) that is 
complementary to the target sequence (Jinek et al. 2012) and binds to it through Watson - Crick 
base pairing (Cong et al. 2013; Sternberg and Doudna 2015) (Figure 6 A). The gRNA 
sequence can bind up to 22-23 base pairs (Hsu et al. 2013), (Ran et al. 2013). The simplicity 
of the target design, the high efficiency of this system and the ability to multiplexing have 
made CRISPR the preferable choice of cell line engineering (Perez-Pinera, Ousterout, and 
Gersbach 2012), (Cox, Platt, and Zhang 2015).  
  
Figure 6. The CRISPR/Cas9 system. (A) Schematic representation of the CRISPR/Cas9 system in complex 
with guide RNA and target DNA. crRNA is matched to the complementary target DNA sequence and is also bind 
to the tracrRNA. (B) Crystal structure of Streptococcus pyogenes Cas9 endonuclease in complex with guide 
RNA and target DNA (Nishimasu et al. 2014). 
For genome editing, the most commonly used and extensively characterized system is type II 
derived from S. pyogenes (SpCas9) (Figure 6 B). Two RNA elements (crRNA & tracrRNA) 
are combined into a single chimeric molecule termed the guide RNA (gRNA) that can be 
simultaneously expressed alongside the Cas9 nuclease (Cho and Chang 2015; Ran et al. 2013; 
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Walsh and Hochedlinger 2013). It has been shown that maintaining the RNA as two separate 
molecules (crRNA:tracrRNA) can enhance cutting efficiency, and may well be desirable for 
some study designs, for example developing a system whereby only the small crRNA is 
changed to affect different outcomes (Aida et al. 2015). The simplicity of this approach is that 
by altering the first 20 nucleotides of the gRNA, Cas9 nuclease can be directed to any DNA 
sequence, adjacent to necessary, short DNA sequences (Protospacer adjacent motif (PAM)) 
(Ran et al. 2013; Sander and Joung 2014). 
3.1.2. The features of Cas9 cleavage 
Three significant steps define the function of the CRISPR/Cas9 system: (1) initially the RNA-
guided Cas9 nuclease (RGN) scans the genome to find the complementary DNA sequence to 
the gRNA, (2) then the induction of a DNA double-strand break by Cas9 takes place, and lastly 
(3) DNA repair cellular machinery repairs the DSB (Hsu, Lander, and Zhang 2014). It is well 
established that after a Cas9-mediated DSB, DNA mutations are generated by the cellular 
machinery. Those mutations determine Cas9 phenotypic efficiency (Allen et al. 2019) with the 
repair process to be in the majority of the cases error-prone at a rate similar to the transfection 
efficiency (Brinkman et al. 2018). Still, the kinetics of a Cas9-mediated DSB and repair are 
not fully understood. However, it is believed that they differ from the kinetics of a natural DSB 
repair presumably because Cas9 remains bound to the target sequence following cleavage 
(Agrotis and Ketteler 2015). Over the past years, several studies have provided insights into 
the mechanisms affecting Cas9-mediated DSB repair and provided useful understandings of 
the process (Brinkman et al. 2018; van Overbeek et al. 2016; Tsai and Joung 2016). 
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The Cas9-mediated cut and repair process  
In a recent study, Brinkman et al. measured the kinetics of a DSB repair after a Cas9-mediated 
cleavage and concluded that during the process of a Cas9-DSB the DNA enters a reversible 
‘‘broken’’ state (Brinkman et al. 2018). They suggest that this state may be repaired correctly, 
or an error-prone repair mechanism can introduce small InDels at the cleavage site. The latter 
state fallouts in an irreversible ‘‘InDel’’ state that can no longer be adequately recognized by 
the gRNA and therefore cannot be cut again by Cas9. Moreover, several other studies 
(Sternberg et al. 2014), (Richardson, Ray, DeWitt, et al. 2016), (A. Shibata et al. 2017) indicate 
that Cas9 remains tightly bound to one or both DNA ends after cutting, and the detachment 
can only happen by protein denaturation. Additional studies have shown that also the 
catalytically inactive Cas9 (“dead” Cas9) is tightly bound to its target DNA in vivo with a dwell 
time of about 2 h (Knight et al. 2015). Overall, data suggest that the rate of DSB repair is 
variable, relatively slow and that the repair process tends to be error-prone (Brinkman et al. 
2018; Rose et al. 2017). In comparison, a natural occurring double-strand break is generally 
repaired within 10 to 60 min. 
Cas9-mediated DSB profile 
Multiple studies have analyzed short-range sequencing data by NGS from the cleavage site 
following a Cas9 mediated gene editing to characterize the repair process. The summary of 
these efforts is the evident accumulation of InDels in the cleavage site of the cells indicating 
an erroneous repair (Brinkman et al. 2018; Cullot et al. 2019). 
More specifically, in a recent study by So and Martin 2019, it was shown that DSBs with 5’ 
and 3’ overhangs lead to increased processing of DNA during end-joining compared to blunt 
DSBs (So and Martin 2019). 5’ overhangs are removed, and 3’ are filled in at recombination 
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junctions, implying that different subsets of enzymes are required for repair based on Cas9 
mediated DSB. These findings, together with other results, explain the prevalence of single-
nucleotide insertions homologous at the cleavage site.  
Furthermore, in a study by Chakrabarti et al. they show that the editing precision of Cas9 is an 
inherent feature of the target site that depends on four nucleotides located around the cleavage 
site within the PAM. Specifically, they highlight the importance of the -4 nucleotide position, 
from the PAM site, as the most influential position. In that position, possibly an overhanging 
nucleotide is created that can be used as a template of single-nucleotide insertions homologous 
since it can be used as a template before the broken DNA ends are rejoined (Anob M. 
Chakrabarti et al. 2019). 
Multiple repair pathways active at one locus 
CRISPR/Cas9 has been successfully used to Knock-Out (KO) or Knock-In (KI) genes of 
interest in cells and zygotes of different species (Rezza et al. 2019). During this process two 
repair mechanisms prevail; c-NHEJ which produces small insertions or deletions (InDels) at 
the cleavage site, or Homologous Directed Repair (HDR) that induces the specific insertion of 
an exogenous DNA fragment at the cut site. 
Apart from these two main repair pathways, recent studies show the implication of additional 
pathways to be active at one DSBs locus (van Overbeek et al. 2016), (Bothmer et al. 2017). 
However, the interplay and relative contributions have remained mostly uncharacterized (Allen 
et al. 2019). Except for HR and c-NHEJ, recent findings also implicate alt-EJ in the process of 
DNA repair after a Cas9-mediated DSB that is thought to be highly mutagenic (Brinkman et 
al. 2018), (So and Martin 2019). Alternative end-joining (alt-EJ), uses short sequence 
Introduction: Chapter 3   Genome engineering and DNA repair assays  
36 
 
homologies near the two ends, which leads to specific small deletions (McVey and Lee 2008). 
Therefore it is believed that both classical and alternative end-joining pathways contribute to 
the erroneous repair (Brinkman et al. 2018), (Allen et al. 2019). In an attempt to measure the 
kinetics of the Cas9 cut and repair process, Brinkman et al. showed that alt-EJ has slower repair 
kinetics than c-NHEJ (Brinkman et al. 2018). They observe that mainly the lower rate is 
because alt-EJ exhibits a delayed onset compared to c-NHEJ rather than a reduced activity. 
Most likely, the c-NHEJ system initially prevents the access of the alt-EJ pathway to the DSB; 
only after several hours if c-NHEJ has failed to repair the break, the alt-EJ pathway is allowed 
to engage (Brinkman et al. 2018). 
Applications of CRISPR/Cas9 
Recently, the prokaryotic immune system, CRISPR/Cas9 has been adapted for genetic editing 
in a variety of systems or organelles including bacteria (J.-S. Kim et al. 2016), (Barrangou et 
al. 2013), fungi (Liu et al. 2015), plants (Belhaj et al. 2013), insects (Alphey 2016), (Bassett 
and Liu 2014), worms (Friedland et al. 2013), zebrafish (Blackburn et al. 2013), mouse (Yin 
et al. 2016) and mammals (Bachu, Bergareche, and Chasin 2015). CRISPR has already 
transformed the field of genome engineering and will likely continue to do so, forming the 
basis of future research and clinical strategies. 
The expansion in CRISPR research is mainly due to the simplicity of targeting; instead of using 
custom in vitro generated proteins, the Cas9 nuclease can be targeted to specific genomic 
regions by a single guide RNA, which is comparably easy to produce. The CRISPR technology 
has rapidly evolved over the past few years, and it seems that several of the drawbacks have 
been mitigated with off-target effects (OTE) to represent an important issue that hinders the 
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use of CRISPR/Cas9 in in vivo applications. (Biagioni et al. 2017; Cho et al. 2014; Kleinstiver 
et al. 2016; Ricci et al. 2019; Tsai and Joung 2016; Zhang et al. 2015). Some possible solutions 
that have been described in the literature are first to evolve the gRNA design algorithms to 
minimize the OTE. Secondly, to use shorter gRNA sequences to decrease the potential 
mismatch tolerance. Thirdly, the concentration of the Cas9/gRNA complex needs to be 
maintained at minimal levels since it influences the OTE. Another possible solution is the use 
of paired Cas9 nickases that increases significantly the target specificity.  
Overall, CRISPR fulfils the criteria that an ideal genome-editing tool should possess (Cong et 
al. 2013): low or negligible off-target mutations (Tan et al. 2015),  (Veres et al. 2014),  (Yang 
et al. 2014), (Sander and Joung 2014), (Anderson et al. 2015), rapid and efficient assembly of 
the nuclease and in high occurrence (1 per 8 bp) of the desired sequence in the targeted cell 
population. In summary, it is this availability and simplicity that allowed genome editing to 
become so attractive. 
3.3. Reporter assays for DNA repair 
The cell’s DNA repair mechanisms try to restore the original DNA sequence after encountering 
DNA damage. Sometimes it repairs without a change or sometimes with mutagenic alterations 
or even recombination events (Gunn and Stark 2012). Over the past decades to detect these 
changes scientists have developed several in vitro reporter assays in various model systems 
(Figure 7) (Bennardo et al. 2008; Bervoets and Charlier 2018; Certo et al. 2011; Gomez-
Cabello et al. 2013; Iliakis et al. 2008; Johnson, Liu, and Jasin 1999; C. Ren et al. 2015; A. 
Shibata et al. 2017; Stark and Jasin 2003). There are assays for DNA damage and repair that 
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can trace and quantify the DNA repair pathway activity, examine the consequences of the 
processing of chromosome rearrangements, and evaluate the repair process of induced DNA 
damage, most frequently of a DSB (Adamson et al. 2012; Certo et al. 2012; Choe, Guo, and 
van den Engh 2005; Kuhar et al. 2016; Rakauskait et al. 2011; Ramirez et al. 2012; Q. Ren et 
al. 2015; A. Shibata et al. 2017). These assays are powerful tools, and each comes with its 
particular advantages and limitations (Klein et al. 2019). 
The first implementation of an in vitro assay was made with the SCneo reporter in 1999 
(Johnson et al. 1999). Roger et al. developed a recombination reporter that contains two non-
functional copies of the neomycin phosphotransferase (neo) gene (Figure 7 A). After the 
induction of a DSB with the I-SceI endonuclease the system allows for the detection of two 
recombination products; short tract gene conversion (STGC) or long-tract gene conversion 
(LTGC). I-SceI endonuclease generates a defined DSB within its 18 base-pair (bp) recognition 
sequence, resulting in DSB ends with 4 nucleotides (nt) 3’ cohesive overhangs. This approach 
helped to identify the involvement of XRCC2 and XRCC3 to DSB by HR (Johnson et al. 1999; 
Pierce et al. 1999) and that sister chromatid gene conversion is a prominent DSB repair 
pathway in mammalian cells (Johnson and Jasin 2000).  
In the years to follow several GFP-based reporters assays with recognition sites for the rare-
cutting endonuclease I-SceI, have been developed to examine the distinct repair outcomes of 
mammalian DNA DSB repair (Gunn and Stark 2012) (Figure 7 A-E). Depending on the 
design, reporters can be used to assess homology-directed repair, single-strand annealing, or 
alternative end-joining. Beginning with DR-GFP, DRins-GFP, SA-GFP, and EJ2-GFP, these 
reporters are designed to examine a series of repair outcomes that utilize homology. DR-GFP 
and DRins-GFP are used to quantify two distinct homology-directed repairs (HDR) events, 
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whereas SA-GFP and EJ2-GFP are used to measure single-strand annealing (SSA) and 
alternative end-joining (alt-EJ) events, respectively. These efforts revealed the importance of 
Nbs1 and CtIP in the initiation of end-resection (Sartori et al. 2007; Stracker and Petrini 2011).  
 
Figure 7: Development of DNA repair assays. (A) Structure of SCneo and predicted HR products. (B) The DR-
GFP contains the SceGFP cassette that is interrupted by a single I-SceI site, along with 5’ and 3’ truncated 
fragment of GFP. iGFP is used as a template to lead to a GFP+/BcgI+ product. (C) Similar to DR-GFP, with the 
addition of a 464 nt insertion that has to be removed during HDR. (D) SA-GFP contains a 5’ fragment of GFP and 
a 3’ fragment of GFP that contains an I-SceI site. The GFP fragments are separated by 2.7 kb and share 266 nt of 
homology. (E) EJ2-GFP contains an expression cassette for a tagged version of GFP that is interrupted by an I-
SceI site and a series of stop condos, which is flanked by 8 nt of homology. (F) Schematic of the Traffic Light 
reporter showing the different engineering outcomes after the induction of DSB by I-SceI. (G) In the See-Saw 
Reporter, a GFP gene is flanked by two truncated parts of the RFP gene (RF and FP) that share 302 bp of 
homologous sequence. Figures adapted from (Johnson and Jasin 2000), (Certo et al. 2011), (Gunn and Stark 
2012), (Gomez-Cabello et al. 2013). 
Apart from these specific reporters some researchers also established reporters to measure the 
activity of specific proteins like the kinase C, CKAR reporter that monitors the activity of 
ATM or other specific proteins in living cells (Johnson, You, and Hunter 2007).  
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So far, these methods have only been focusing on the study of specific DDR pathways and 
were driven by the target design, failing to provide an overall understanding of the complexity 
of double-strand break repair. In 2011 Certo et al. developed the Traffic Light Reporter (Certo 
et al. 2011) implementing a reporter assay for the first time to a high-throughput genetic screen 
(Figure 7 F). Several studies followed this approach in an effort to identify novel target genes 
involved in DNA-damage response with great success (Adamson et al. 2012; Bervoets and 
Charlier 2018; Goglia et al. 2015; Gong et al. 2015; Kojima and Borisy 2014; López-Saavedra 
et al. 2016; Q. Ren et al. 2015; A. Shibata et al. 2017). 
The recent expansion of genome engineering have recently brought the CRISPR/Cas9 system 
(Ran et al. 2013), (Doudna and Charpentier 2014), in the footsteps of reporter systems to induce 
highly site-specific DSBs instead of I-SceI (He et al. 2016; Q. Ren et al. 2015; Wen et al. 
2017). In this Ph.D. thesis, we describe the development of a dual-fluorescent reporter coupled 
to CRISPR/Cas9 technology, providing an opportunity to advance our knowledge of DSB 
repair and study the interplay among DNA DSB repair pathways.  
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Chapter 4 
Aims 
To study the DNA double-strand break repair choices in vitro, we developed and employed 
Colour Assay Tracing Repair (CAT-R) as a dual-fluorescence reporter-based system. This 
study is conducted at the DNA Damage in Cancer group at BioMed X Innovation Centre.  
 
The main aims of this research are to:  
▪ Develop a novel method to trace the DNA repair status after a Cas9-mediated DSB. 
▪ Establish a platform to screen small pharmacological compounds related to DSB. 
▪ Evaluate the importance of individual DNA repair components on DSB repair choice.  
▪ Estimate the impact of the genetic background in DNA repair choice. 
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Chapter 5 
CAT-R fluorescent reporter 
This chapter describes the development of the tandem fluorescent reporter (CAT-R) that takes 
advantage of the highly efficient and precise CRISPR/Cas9 based double-strand break (DSB) 
induction to assess in vitro the different DNA repair outcomes.  
Custom model cell lines were engineered with the Flp recombinase to integrate the fluorescent 
reporter as a single stable copy to the cell's genome. Besides, the cells were engineered to 
express the enzymatically active Cas9 endonuclease in a doxycycline-inducible format. 
Furthermore, the transfection conditions and the timing of analysis were optimized to ensure 
high reproducibility in both model cell lines achieving an unparalleled resolution of the DSB 
events. 
CAT-R distinguishes small insertions or deletions (InDels) from large deletions allowing the 
simultaneous measurement of the rates of end-protection and end-resection DNA repair 
mechanisms in human cell lines. In this chapter, it is shown that DNA repair deficiencies can 
alter the rate between InDels and large deletions by directing the repair of the DSBs to either 
end-protection or end-resection based mechanisms.  
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5.1. Custom cell line engineering 
Expressing vectors designed for use with the Flp-In™ System 
Transformed human embryonic kidney (Flp-In™ HEK293, Life technologies) and human 
telomerase reverse transcriptase (hTERT)-immortalized retinal pigment epithelial (hTERT T-
Rex™ RPE-1, a kind gift from Jonathon Pines) mammalian cell lines were used as model 
systems to integrate the custom-made DNA fluorescent reporter as a single stable copy to the 
cell’s genome with the use of Flp-In™ system. The Flp recombinase-mediated integration 
approach (Flp-In™, Invitrogen™) has been used widely to generate stable mammalian 
expression cell lines (Callesen et al. 2016; Ji et al. 2017; Sabath and Shim 2000; Theodosiou 
and Xu 1998). It uses the flippase (Flp) recombinase to recombine DNA sequences between 
short flippase recognition target (FRT) sites.  
According to the manufacturer’s protocol (Flp-In™ System), cells were transfected and 
expanded for one week. Since the integrated gene of interest contains fluorescent proteins, 
FACS sorting was used as an application for the selection of positive cells. 
Generating stable cell lines expressing Cas9 endonuclease 
The Edit-R inducible lentiviral Cas9 particles (Horizon™ Dharmacon) were used to generate 
Cas9 expressing cell lines that employ the Tet-On 3G induction system allowing for a robust 
Cas9 induction at doxycycline doses between 100 ng/ml and 1 μg/ml. The lentiviral Cas9 
particles confer Blasticidin resistance in transduced cells, therefore it is important to determine 
the minimum required Blasticidin concentration that kills the un-transduced cell lines. 
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Therefore, concentrations ranging from 2.5-20 μg/ml of Blasticidin were tested in both 
HEK293 and RPE-1 cell lines. Within 3-15 days after the addition of Blasticidin (0, 2.5, 5, 10, 
15, 15, 20 μg/ml) both cell lines exhibit resistance to the highest dose of Blasticidin (Figure 8 
A). 
 
Figure 8: Determining Blasticidin sensitivity and schematic representation on the workflow for knocking 
it out. (A) Raw pictures of HEK293CAT-R and RPE-1CAT-R cell lines after applying crystal violet. The cells were tested 
at increasing concentrations of Blasticidin (2, 2.5, 5, 10, 15, 20 μg/ml). Both cell lines are resistant to Blasticidin. 
(B) Workflow scheme. Cell lines were individually treated with an all-in-one vector to knockout the Blasticidin gene. 
Then cells were single-cell expanded for 2 - 3 weeks. Subsequently, approximately 10 clones were transferred to 
a larger plate and allowed to reach confluency. Colonies were split 1:2 and Blasticidin was applied to the medium. 
After one-week crystal violet was used to visualize the colonies. Images were taken for each plate. 
To disrupt the Blasticidin sequence and generate single knock-out (KO) clones sensitive to 
Blasticidin, the CRISPR/Cas9 system was used. Specific gRNAs targeting the Blasticidin 
sequence were designed and cells were transfected with an all-in-one vector (Figure 8 B). 
Overall, ten monoclonal cell lines sensitive to Blasticidin were generated that could be used 
with the Edit-R inducible lentiviral Cas9 particles. 
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After transducing the cell lines with the Edit-R inducible lentiviral Cas9 particles (hereafter 
referred to as HEK293CAT-R and RPE-1CAT-R cells), cells were cultured for seven days in 
selection medium supplemented with 1 μg/ml Blasticidin. Protein extracts from mixed cell 
populations were used to determine the expression levels of Cas9 protein in an inducible 
manner in the presence of doxycycline by western blotting using an anti-Cas9 antibody (Figure 
9). 
 
Figure 9: Western blot detecting Cas9 expression. Western blot from a mixed cell population from both cell 
lines (HEK293CAT-R, RPE-1 CAT-R) shows that under Doxycycline induction the expression of the Cas9 protein is 
induced. Blots were incubated with antibodies directed against Cas9 and GAPDH. 
5.2. Optimizing transfection and Cas9 cutting efficiency 
To establish and optimize the conditions of the double-strand break (DSB) induction are 
described to ensure high reproducibility in HEK293CAT-R and RPE-1CAT-R cells (Figure 10 A), 
several conditions have been considered such as (1) the effect of cell population density on 
transfection efficiency, (2) the type and optimal concentration of transfection reagent, and 
lastly (3) the ideal time point of analysis. 
It is widely acknowledged that some “cargo” types such as longer pieces of DNA or proteins 
are difficult to get into cells. Therefore, the transfection efficiency of both cell lines was 
evaluated by quantifying the levels of eGFP expression three days post-transfection with the 
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same pDNA vector (LentiGuide puro eGFP), lipid-mediation reagent (Lipofectamine™3000) 
and lipid to DNA ratio (1:3). The maximum transfection efficiency achieved in normal 
HEK293 was approximately 80%, whereas for normal RPE-1 the efficiency had a maximum 
of 55% (Figure 10 B). Even though 55% of transfection efficiency is can be considered high 
under certain conditions, our experimental pipeline requires higher rates since a build-in cell-
based assay is developed for large-scale screens with several gene-edited transgenic cell lines 
to be used and a robust phenotype needs to occur every time.  
 
Figure 10: Ensuring system quality performance. (A) Ideal cell confluency 24 h after seeding 20.000 cells 
HEK293 and 8.000 cells RPE-1 in a 96 well plate intended for a liquid transfection. (B) Transfected wild type RPE-
1 and HEK293 with the same eGFP expressing vectors (LentiGuide puro eGFP) with Lipofectamine™3000 in 1:1.3 
DNA to lipid ratio. The effect of Cationic lipid-DNA complex ratio on lipid-mediation transfection efficiency in RPE-
1 cell lines. (C) The pDNA vector (LentiCRISPR eGFP) is used to transfect RPE-1 cells with different lipid-mediation 
reagents (JetPrime®Polyplus, FuGene®Promega, ScreenFect®, Lipofectamine™2000, Lipofectamine™ 3000) at 
various lipid: DNA ratios. The pDNA vector expresses the eGFP protein and is used to quantify the expression 
levels of it with flow cytometry. (D) The efficiency of different gRNA format is tested in a time-dependent manner 
(24, 48, and 72 hr) in HEK293CAT-R and RPE-1CAT-R cells. The eGFP reduction is checked with flow cytometry. The 
same gRNA sequence is used in all formats. A standard student t-test is used to calculate the P-values between 
untreated and treated samples. pDNA: px330), RNA: in-vitro transcribed (IVT) or synthetic crRNA:tracrRNA gRNA. 
The efficient delivery of the CRISPR reagents into the cells ensures a higher probability of 
success for any downstream application. For this reason, we examined several transfection 
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reagents such as Lipofectamine™ 3000, JetPrime®Polyplus, FuGene®Promega, 
ScreenFect®, at different concentrations, and formats (pDNA, RNA) to further boost the 
transfection efficiency of the CRISPR reagents into the model cell lines. To optimize the 
delivery of pDNA vectors to HEK293 and RPE-1 cell lines we tested different lipid-reagent 
(μl) to DNA concentration (μg) ratios in ranges from 0.7 to 6 with several transfection reagents 
(Figure 10 C). Lipofectamine™ 3000 and JetPrime®Polyplus exhibit the highest transfection 
efficiencies (approximately 55%) in RPE-1 with lipid:DNA ratio to range from 1.3 up to 3, 
whereas FuGene®Promega and ScreenFect® displayed signs of transfection at much higher 
lipid:DNA ratios (3 to 6). Among all transfection reagents, Lipofectamine™ 3000 and 
JetPrime®Polyplus had the least cytotoxic effects after three days of transfection. Probably the 
higher amount of lipid-reagent that was needed in the case of FuGene®Promega and 
ScreenFect® reagents was the causal for the severe cytotoxicity.  
As defined above, the maximum transfection efficiency of a pDNA for normal HEK293 and 
RPE-1 was measured at 80% and 55% respectively. However, transfection efficiency may not 
necessarily translate into similar levels of a functional read-out. Therefore, to maximize the 
Cas9-mediated DSB read-out, two different gRNA formats (pDNA, RNA) of the same gRNA 
sequence were examined by comparing the levels of eGFP reduction in a time-course manner 
(Figure 10 D). 
The use of a pDNA vector reduces the expression levels of eGFP 48 h post-transfection on 
average only by 25% in both cell lines (Figure 10 D). While 72 h post-transfection the 
reduction of eGFP expression was about 60% for HEK293CAT-R and still 35% for RPE-1CAT-R. 
Subsequently, the pDNA vector format cannot carry adequate CRISPR reagents to the cells for 
the induction of an effective phenotype. 
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Instead, when transfecting the gRNA sequence in an RNA format significantly higher results 
are achieved. Even at 48 h post-transfection the reduction of eGFP expression for 
HEK293CAT-R was about 75% and 55% for RPE-1CAT-R (Figure 10 D). Those numbers were 
further increased 72 h post-transfection with both cell lines achieving a reduction to the levels 
of eGFP at about 85%, with similar efficiencies to have been reported before (Agrotis and 
Ketteler 2015). 
 
Figure 11: The cutting efficiency is examined with the SURVEYOR assay. Genomic cleavage analysis of the 
eGFP genomic loci targeted with the synthetic gRNA in (A) HEK293CAT-R and (B) RPE-1CAT-R cells. The efficiency 
of the gRNA is studied for 24 to 72 h post-transfection with the SURVEYOR assay. Products from untreated control 
cells and cells transfected with the CRISPR system were analyzed in a 1.5% agarose gel electrophoresis. 
Moreover, to further investigate the optimal conditions for a Cas9-mediated DSB read-out, we 
evaluated the genome editing efficiency based on an enzymatic mismatch cleavage assay 
(Langhans and Palladino 2009) in a time-course manner for both cell lines of interest (Figure 
11). A successful editing event can already be detected 24 h post-transfection with the RNA 
format in both cell lines. Whereas signs of an efficient double-strand break were visible with 
the pDNA only 48 h post-transfection. In addition, the intensity ratio between intact DNA and 
cleavage products between pDNA and in vitro transcribed (IVT) RNA at 48 h was much higher 
for the RNA format compared to the pDNA, indicating a better double-strand break induction. 
Overall, the cutting efficiency measured by the Surveyor nuclease showed similar results in 
terms of efficiency and timing as with our previous efforts. 
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Collectively, the data suggest that to maximize the Cas9-mediated DSB read-out the synthetic 
(crRNA:tracrRNA) gRNA format should be used, in lipid to RNA ratio 1:2, with 
Lipofectamine™RNAiMAX as a transfection reagent in the model cell lines HEK293CAT-R and 
RPE-1CAT-R. In addition, the optimal time point of analysis varies between three- to four-days 
post-transfection for a robust phenotype. 
5.3. Color assay tracing repair 
We designed an in vitro reporter assay named the Color-assay tracing repair (CAT-R). It 
consists of two coding sequences for the fluorescent proteins mCherry and eGFP linked with 
a self-cleaving P2A peptide and is integrated at a single genomic locus in human HEK293 and 
RPE-1 cells, engineered to express the doxycycline-inducible Cas9 endonuclease (Figure 12 
A). To generate a single site-specific DNA double-strand break, we used a gRNA targeting the 
eGFP coding sequence in doxycycline-induced HEK293CAT-R cells. Three days post-
transfection the repair outcome is analyzed with flow cytometry and plotted as a density plot 
of mCherry and eGFP expression (Figure 12 B). The repair of this double-strand break can 
potentially give rise to three populations with distinct fluorescent signals: (i) in the first case, 
a frameshift mutation places only the eGFP coding sequence out of frame (mCherry+/GFP-) 
due to repair by small insertions/deletions (InDels); (ii) in the second case, deletions larger 
than approximately 250 bps leads to loss of both mCherry and eGFP sequences (mCherry-
/GFP-) and (iii) in the third case if the repair is error-free, then both mCherry and eGFP 
sequences remain intact (mCherry+/GFP+). Comparing the phenotypes observed upon gRNA 
targeting eGFP with a non-targeting (scrambled) gRNA, indeed we could observe three 
different populations, two of which correspond to error-prone and one to error-free repair of 
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the double-strand break. Even though we achieve very high transfection efficiencies (greater 
than 80%) in HEK293CAT-R cells, this third population likely represents a combination of 
untransfected cells and cells underwent an error-free repair (Figure 12 B).  
 
Figure 12: The Color Assay Tracing repair (CAT-R) reporter. (A)  Schematic representation of CAT-R reporter 
illustrating the different DNA repair outcomes after a Cas9-mediated site-specific double-strand break (DSB). Arrow 
represents promoter and initial mCherry start codon. The CRISPR/Cas9 site is indicated at the eGFP loci 355 bp 
downstream of P2A. If the break is resolved through end-protection pathways, small insertions/deletions (InDels) 
will form at the break site that will translate eGFP out of frame, and only the mCherry will be expressed; if the break 
is resolved through end-resection pathways, both mCherry and eGFP sequence will be translated out of frame due 
to the formation of large InDels. (B) Flow cytometry analysis plot of HEK293CAT-R cells 72 h post-transfection with 
the synthetic crRNA:tracrRNA complex. Comparing the phenotypes between a non-targeting (scrambled) gRNA 
to a gRNA targeting the eGFP sequence, we observe three fluorescent populations to form. Numbers inside plots 
indicate percentages of live cells. Axes report relative fluorescence intensity in arbitrary units. (C) Quantification 
box and whisker plot (min to max) of flow cytometry analysis for HEK293CAT-R and RPE-1CAT-R cell line 72 h post-
transfection with the synthetic crRNA:tracrRNA complex. A standard student t-test is used to calculate the P-values 
between untreated and treated samples per population. (D) Flow cytometry analysis of HEK293CAT-R cells 72 h 
post-transfection with six different synthetic gRNA complexes targeting the eGFP sequence. All gRNAs induce a 
double-strand break with a similar effect. Numbers inside plots indicate percentages of live cells. Axes report 
relative fluorescence intensity in arbitrary units. 
The population frequency suggests that the DNA repair choice is on average 1.1 (±0.2) for 
HEK293CAT-R between InDel formation and large deletions with error-free repair to be very 
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rare (Figure 12 C). This result is not specific to HEK293CAT-R cells, as RPE-1CAT-R cells also 
showed an equal representation of these two error-prone populations. In RPE-1 cells, however, 
the formation of the small InDels was slightly higher than that of HEK293 cells in a ratio of 
small InDels to large deletions to be on average 1.4  (±0.1) (Figure 12 C). To confirm that the 
choice of gRNA did not affect the relative frequencies of these two populations, we 
additionally designed five more gRNAs targeting different regions of the eGFP sequence. In 
all cases, we observed similar results, with an average ratio of small InDels to large deletions 
to be 1.4 (±0.2). Collectively, our results suggest that upon CRISPR/Cas9 mediated DSB, both 
small InDels, and large deletions can occur at similar frequencies (Figure 12 D). 
Integrating cell cycle with the DNA damage repair  
To gain more insights into the kinetics of a Cas9-mediated DSB, we monitored for four days 
the repair process with a live cell imaging system (IncuCyte, Sartorius) (Figure 13 A). The 
results demonstrate that after a Cas9-mediated DSB the repair process commences as early as 
12 ±2 hours post-transfection, agreeing well with similar outcomes of recent studies (Brinkman 
et al. 2018; Anob M Chakrabarti et al. 2019; Kosicki, Tomberg, and Bradley 2018). 
Furthermore, to confirm that these populations are indeed products of erroneous DSB-repair 
and are stably maintained, we monitored the cell division for seven days following a DSB 
induction. We observed that the fluorescence intensity of mCherry and eGFP reduces over time 
without drastically changing the ratios among these populations (Figure 13 B).  
Moreover, the control of DNA repair by the cell cycle checkpoints has been well described 
(Ghelli Luserna di Rora’, Iacobucci, and Martinelli 2017; Hustedt and Durocher 2017; Mjelle 
et al. 2015; Stracker et al. 2009). Typically, the cell cycle is arrested at specific points to give 
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cells the necessary time to repair the DNA damage before proceeding to division. Certain cell 
cycle points involve different DDR pathways that give rise to distinct DNA repair outcomes. 
For instance, c-NHEJ, which is a major contributor to small InDels, is active throughout the 
cell cycle, whereas end-resection, that leads to large deletions or error-free repair, is generally 
restricted during late S and G2 phase.  
 
Figure 13: The control of DNA repair by the cell cycle. (A) Fluorescent images are showing the different repair 
outcomes 72 h post-transfection. Only red fluorescent cells indicate an end-protection repair, whereas no 
fluorescence cells refer to end-resection repair. Green & red fluorescence cells indicate the untransfected or cells 
that underwent error-free repair. (B) Time course tracking for HEK293CAT-R cells following a DSB induction 
throughout 2, 5, and seven days. (C) Cell cycle profile of untreated HEK293CAT-R and RPE-1CAT-R cells. A standard 
student t-test is used to calculate the P-values between cell lines in every cell cycle phase. (D) Cell cycle profile of 
sorted HEK293CAT-R cells populations. 
Therefore, we evaluated the cell cycle profile of the HEK293CAT-R and RPE-1CAT-R to better 
explain the slight differences in the ratio of small InDels to large deletions. When compared 
the cell cycle profiles of both cell lines, we observed that RPE-1 cells spend relatively less time 
in the S and G2 phase comparing to HEK293 (Figure 13 C). That could explain why RPE-1 
cells have a lower frequency of large deletions than HEK293. Moreover, we questioned 
whether the two DNA repair outcomes are a product of cell cycle stalling. Therefore we sorted 
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cells based on their DNA repair profile outcome, small InDels or large deletions, and compared 
their cell cycle profile (Figure 13 D). No significant differences occurred, suggesting that both 
cell populations are indeed products of erroneous DSB-repair and not products of cell cycle 
stalling. Overall, these results imply that the Cas9 cut and repair process is not profoundly 
affected by the cell cycle. 
Regulation of DNA repair pathway choice by homologies 
Long-homology and micro-homology sites are used by the DNA repair sensor complexes, like 
PARP1, to influence the outcome of the DNA repair in terms of pathway choice (Ceccaldi et 
al. 2016; Ray Chaudhuri and Nussenzweig 2017). Therefore, it is crucial to understand the 
homology sites and their frequency at the loci of interest. To do so, we used the basic local 
alignment search tool (BLAST) (https://blast.ncbi.nlm.nih.gov/Blast.cgi), which allows the 
identification of regions with local similarity across the FRT integration site (a 14.673 bp DNA 
sequence). Two regions of long homologies (LHM; > 100 bp) are located at the S40 poly(A) 
signal, and at the ampicillin resistance sequence that could possibly justify for long DNA losses 
after a DNA double-strand break (Figure 14). This type of DNA repair would result in an 
increase of the mCherry-/GFP- population.  
Furthermore, focusing more on the region of the CAT-R system (a 2.586 bp DNA sequence) 
we identified three potential microhomology sites (MHM; 20 – 50 bp) between the mCherry 
and eGFP sequence. Those microhomologies theoretically could be sensed by PARP1 to 
enable alternative end-joining pathway (alt-EJ) that would lead to the loss of both fluorescence 
proteins function in this locus. 
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Figure 14: Schematic representation of the entire FRT integration site in the model cell lines. At the entire 
FRT integration site, two sites of long-homologies (> 100 bp) are identified, one at the SV40 poly(A) signal and 
another at the Ampicillin resistance sequence. In addition, at the CAT-R system, a 2.586 bp length DNA sequence, 
three potential microhomologies sites are identified across the double-strand break site (guide5). LHM: Long-
homology, SHM: Microhomology, MHM: Microhomology. 
Additionally, more than 50 small microhomologies (SHM; 1 - 10 bp) of different base-pair 
length and type are identified across the double-strand break site (guide5) with the use of an 
online available tool (www.rgenome.net). If in this case, small microhomologies are used 
during the repair process after a DSB, then only the eGFP sequence would be translated out of 
frame resulting in an increase of the mCherry+/GFP- population. 
Mutational profile of small InDels 
To further understand the repair patterns and outcomes of a Cas9-mediated DSB, we performed 
targeted next-generation sequencing (NGS) to detect the frequency of the InDels at the affected 
site. Genomic DNA was harvested from cells 72 h post-transfection and a two-step PCR 
protocol was employed to prepare the PCR products for amplicon sequencing. 
The analysis of the amplicons showed that the maximum length of deletion that we detected 
was 171 bps, and for the majority of the cases (99%) the size of InDels was less than 50 bps 
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when counting events with more than 1% frequency (Figure 15 A). The most common type of 
event was 1 bp deletions and 1 bp insertions, with 1 bp insertions to exclusively consist of an 
adenine “A” at the repair site supporting the idea of templated insertions (Shen et al. 2018) at 
the DSB site (Figure 15 B). Interestingly, microhomology-mediated end repair deletions of 11 
and 24 bps were also often (5.7% and 3.1% frequency, respectively) (Figure 15 C). An in-
depth analysis revealed seven different microhomology (MH) patterns supporting deletions of 
various bps length, with the “AC” and “GG” MH patterns to be the most common.  
 
Figure 15: Mutational profile of InDels (A) Deep targeted next-generation sequencing to detect InDels at the 
targeted site from genomic DNA harvested 72 h after transfection. The frequency of events that occur after a Cas9-
mediated DSB in almost all cases (~ 99%) are InDels smaller than 50 bps. The most common events were 1 bp 
deletions and 1 bp insertions, with 1 bp insertions to exclusively consist of an A at the repair site supporting 
templated insertions at the DSB site. (B) Profile of the inserted nucleobase type. (C) The pattern of 
microhomologies supporting deletion length. 
The findings from the CAT-R and recent studies suggest that large deletions occur frequently 
after a Cas9-mediated DSB (Cullot et al. 2019; Gasperini et al. 2017; Kosicki et al. 2018). 
However, since larger deletions are technically challenging to observe by short-read NGS, their 
contribution to the DSB repair is less studied. 
CAT-R as a Homologous Recombination reporter 
Recently it was reported (Glaser, McColl, and Vadolas 2016) that the green fluorescent protein 
(GFP) could be converted to a blue fluorescent protein (BFP) by a change of a single amino 
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acid: from Proline (CCT) to Alanine (GCC). This simple modification allowed us to accurately 
measure the single-strand template repair (SSTR) by providing a single strand 
oligodeoxynucleotide (ssODN) as a donor template together with the gRNA targeting the 
eGFP sequence. Previous studies have implemented this approach to quantify knock-in events 
with the conversion rate to be around 3% when lipid-mediation transfection is used (Janssen 
et al. 2019; Y. et al. 2017). With this adaptation, CAT-R could be used as a homologous 
directed repair (HDR) reporter, and the repair of the Cas9-mediated DSB could give rise to an 
additional population with distinct fluorescent signals: mCherry+/BFP+ which corresponds to 
an SSTR event (Figure 16 A). We optimized our reporter with the use of a sense and an anti-
sense gRNA in combination with symmetric and an asymmetric ssODN (Figure 16 B). We 
tested two asymmetric donors' designs with their length to vary from 123 to 136 bps. The 
ssODN(L) bares the extended homology arm on the 5’ end, and the ssODN(R) has the extended 
homology arm on the 3’ end. In overall, the use of the ssODN(L) overperforms the ssODN(R), 
and the symmetric ssODN in terms of SSTR frequency (Figure 16 C). This indicates that there 
is a preference in ssODN symmetry to designs baring extended 5’ homology arms. In 
HEK293CAT-R, the highest SSTR frequency that we achieved was 4.9% (±1.2) with the 
combination of the ssODN(L) asymmetric donor and a sense gRNA (Figure 16 D). 
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Figure 16: CAT-R as a Homologous Recombination reporter. (A) Representation of the CAT-R reporter with 
the supply of an external donor template as a single-stranded oligodeoxynucleotide (ssODN). The ssODN bears 
the necessary nucleotide changes to convert a Green fluorescent sequence to a Blue fluorescent sequence 
indicating a homologous recombination event. (B) The ssODN bares 2 mutations that change the amino acid from 
Proline to Alanine so that instead of the GFP the BFP is produced indicating a knock-in event via the single-strand 
template repair pathway. The asymmetric design of donor templates is also illustrated. (C) A box and whiskers plot 
(min to max) showing the frequency of conversion of GFP to BFP with the use of an asymmetric ssODN template 
in cells that are transfected with the gRNAs that are depicted. A minimum of three biological replicates is used. (D) 
Representative flow cytometry analysis plots of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA 
and the ssODN. Numbers shown inside plots indicate percentages of live cells. Axes report relative fluorescence 
intensity in arbitrary units. The conversion from GFP to BFP is quantified based on the control. 
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5.4. DNA repair deficiencies influence the CAT-R response 
We hypothesized that DNA repair deficiencies could modulate the frequency of the two error-
prone populations. Since DSB repair choices can alternate between end-protection and end-
resection based mechanisms, we examined the response of CAT-R reporter, without the use of 
a ssODN, to specific defects in DSB response.  
Deficiency in end-protection decreases small InDels 
Using the CRISPR/Cas9 system we first generated single knock-out (KO) clones of PRKDC 
and XRCC4, which are two of the most critical components of the c-NHEJ pathway, mediating 
end-protection based DSB repair (Davis and Chen 2013). For each gene of interest one gRNA 
is used to transfect the HEK293CAT-R cells (Figure 17 A). Afterward, monoclonal cell lines are 
generated by limiting dilution and once fully-grown clones are selected for validation. The KO 
efficiency is validated by immunofluorescence for PRKDC (Figure 17 B), and by 
immunoblotting for XRCC4 (Figure 17 C).  
In these two custom-made cell lines, we evaluated the phenotype of the CAT-R reporter in 
response to defects in end-protection pathways (Figure 17 D). In agreement with our 
hypothesis, we observed the involvement of c-NHEJ in the formation of small InDels, in both 
cell lines upon DSB induction we observe a substantial reduction in the formation of small 
InDels on average by 31% (±7) together with an increase in the formation of large deletions 
(Figure 17 E). More specifically, loss of XRCC4 decreases the frequency of small InDels by 
37% (±2), whereas the loss of PRKDC results in a reduction of small InDels by 25% (±1) 
(Figure 17 F). This slight difference might be explained by the fact that PRKDC is involved 
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during the early steps of c-NHEJ, whereas XRCC4 is involved during the last steps. Therefore, 
cells might have not fully committed to this type of end-joining repair and possibly they have 
repaired alternatively, hence the higher frequency of small InDels population. 
 
Figure 17: DNA repair deficiencies in end-protection influence CAT-R response. (A) Schematic workflow of 
generating custom deficient cell lines. (B) Validation of custom made PRKDC-/- HEK293CAT-R cell line by 
immunofluorescence (IF). IF against PCNA and PRKDC in wild type and KO cells. (C) Validation of custom made 
XRCC4-/- HEK293CAT-R cell line by western blot. Western blot against XRCC4 and GAPDH. (D) Schematic workflow 
of KO cell lines evaluating the CAT-R response to DDR deficient background. Representative flow cytometry 
analysis plot of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA targeting the eGFP coding 
sequence in (E) PRKDC and XRCC4 KO cells. Numbers inside plots indicate percentages of live cells. Axes report 
relative fluorescence intensity in arbitrary units. Quantification plots of flow cytometry analysis for HEK293CAT-R 
deficient cells are shown in (F). Data presented in box and whiskers (min to max) with 7 biological replicates. 
Deficiency in end-resection decreases large deletions 
Next, we tackle end-resection based repair pathways by targeting some of the critical molecules 
of homologous recombination (HR) and Fanconi anemia (FA) such as BRCA1, BRCA2, 
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USP1, and several FANC genes. The generation of KO cell lines in critical genes in this class 
may not be possible supporting the notion of essentiality of some of these genes for cell 
survival (Pearl et al. 2015). Therefore, in this case, we transfected cells with synthetic gRNA 
complexes targeting these genes (Figure 18 A) to generate a pool of cells with a defective end-
resection background.  
  
Figure 18: DNA repair deficiencies in end-resection influence CAT-R response. (A) Schematic workflow of a 
pool of CRISPR/gRNA transfected cell lines evaluating the CAT-R response to DDR deficient background. (B) 
Representative flow cytometry analysis plot of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA 
targeting the eGFP coding sequence in a pool of CRISPR/gRNA transfected cells. Numbers inside plots indicate 
percentages of live cells. Axes report relative fluorescence intensity in arbitrary units. (C) Validation of RNA levels 
reduction by RT-qPCR expression analysis in HEK293CAT-R 72 h after crRNA:tracRNA transfection. Quantification 
plots of flow cytometry analysis mixed pool CRISPR/gRNA transfected cells are shown in (D). Data presented in 
box and whiskers (min to max) with a minimum of 12 biological replicates. 
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Consistent with the idea that end-resection can lead to large deletions, knocking out essential 
genes involved in end-resection led to an increase in the formation of small InDels on average 
by 10% (±5) and a decrease in the formation of larger deletions (Figure 18 B). The level of 
KO efficiency is controlled by measuring the RNA levels of the transfected cells three days 
post-transfection by quantitative polymerase chain reaction (RT-qPCR) (Figure 18 C). The 
strongest phenotype is observed when BRCA1 and USP1 are KO. Both proteins are 
collaborating when chromatin remodelers unwind the DNA structure allowing for end-
resection based repair. The role of BRCA1 and USP1 is to further support the end-resection by 
activating ATR, CHK1, and APC (Brown and Jackson 2015; Mjelle et al. 2015; Murai et al. 
2011). The absence of  BRCA1 and USP1 increases the frequency of small InDels by 15% 
(±3), and 13% (±3) respectively with the simultaneous reduction of large deletions as well as 
the frequency of error-free repair (Figure 18 D). 
ATM deficiency increases the frequency of large deletions 
We also wanted to analyze how ATM deficiency affects CAT-R response. On the one hand, 
ATM is stimulating DSB end-resection through phosphorylation and activation of the nuclease 
enzymes such as CtIP, MRE11, EXO1, and BLM. On the other hand, ATM also mediates end-
protection through phosphorylation of DNA-PKcs and the recruitment of Artemis (Jiang et al. 
2015). In order to delineate the potential role of ATM in resolving DSBs, we generated an 
ATM KO cell line (Figure 19 A) and validated the KO efficiency of each single-cell clone by 
western blot. More specifically, the levels of ATM protein along with the levels of phospho-
CHK2 protein, a downstream target of ATM, were detected in the presence of 1μM of 
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doxorubicin, a DNA damage reagent. In half of the tested clones, the ATM was successfully 
KO since the protein of both ATM and p-Chk2 was not present. 
Next, we analyzed the repair upon a single double-strand break with CAT-R (Figure 19 B).  
In this case, ATM deficiency caused a decrease in small InDels on average by 3% (±1) and an 
increase in larger deletions presumably affecting end-protection based repair (Figure 19 C).   
 
Figure 19: ATM deficiency influences DNA repair choice. (A) Validation of custom-made ATM-/- HEK293CAT-R 
cell line by immunoblotting. Western blot against ATM and p-CHK2 after incubation with 1 μM of Doxorubicin for 
1.5 h. (B) Representative flow cytometry analysis plots of HEK293CAT-R cells 72 h post-transfection with the 
synthetic gRNA targeting the eGFP coding sequence in ATM KO cells. Numbers inside plots indicate percentages 
of live cells. Axes report relative fluorescence intensity in arbitrary units. Box and whisker plots (min to max) of flow 
cytometry analysis for HEK293CAT-R deficient cells are shown in (C). Data presented with a minimum of 18 biological 
replicates.  
PARP1 deficiency reduces the frequency of small InDels 
Next, we analyzed how CAT-R can respond to PARP1 deficiency. PARP1 plays an integral 
part during the repair of single-strand breaks. However, how it contributes to the repair of 
DSBs is less well defined, although it was suggested to play diverse roles in the repair of DSBs 
(Wei and Yu 2016). On the one hand, it is suggested to play a role during end-resection by 
rapid recruitment of MRE11 nuclease to the sites of DNA DSBs as well as later stages of HR 
presumably by limiting the amount of end-resection (Hengel et al. 2017). By recruitment of 
MRE11, PARP1 may also be involved in alternative end-joining. 
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On the other hand, it is also reported to stimulate c-NHEJ by interacting with and activating 
DNA-PKcs. To delineate the potential role of PARP1 in resolving DSBs, a PARP1 KO cell line 
is generated (Figure 20 A) and the repair upon a single double-strand break was analyzed 
(Figure 20 B). In this case, PARP1 deficiency caused a decrease in small InDels on average 
by 6% (±1) and an increase in larger deletions, suggesting a more prominent role of PARP1 in 
either end-protection mediated repair or alt-EJ (Figure 20 C). 
 
Figure 20: PARP1 deficiency influences DNA repair choice. (A) Validation of custom made PARP1-/- 
HEK293CAT-R cell line by immunofluorescence (IF). IF against PCNA and PARP1 in wild type and KO cells. (B) 
Representative flow cytometry analysis plots of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA 
targeting the eGFP coding sequence in PARP1 KO cells. Numbers inside plots indicate percentages of live cells. 
Axes report relative fluorescence intensity in arbitrary units. Box and whisker plots (min to max) of flow cytometry 
analysis for HEK293CAT-R deficient cells are shown in (C). Data presented with a minimum of 18 biological 
replicates. 
 
Deficiency in PRKDC and PARP1 reduces the frequency of small 
InDels by alternative types of repair 
We have established so far that the loss of function of either PRKDC or PARP1 is decreasing 
the formation of small InDels (Figure 21 A). More specifically, the results from CAT-R show 
that in a PRKDC KO background small InDels are heavily reduced by 25% (±1), whereas in a 
PARP1 KO background small InDels are reduced by 4% (±4) (Figure 21 B). Even though both 
genes show a similar phenotype, the underlying mechanism of DNA repair differs. It is known 
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that microhomologies (MH) are the designated pattern of repair for alt-EJ, a pathway in which 
PARP1 is a prominent member. Therefore, to detect the different types of InDels that are 
generated when PRKDC and PARP1 are absent we performed deep targeted next-generation 
sequencing (NGS). Genomic DNA was harvested from cells 72 h post-transfection and a two-
step PCR protocol was employed to prepare the PCR products for amplicon sequencing. 
First of all, the data show that once PRKDC is lost, there is a significant reduction in the 
diversity of the various length types (Figure 21 C) such as deletions of 7-, 8-, 9-, 10-bp which 
are completely missing. Whereas at the same time, in a PARP1 deficient background a notable 
increase (13%) in the frequency of 1 bp insertions is observed with the simultaneous reduction 
of the 2-, 11-, and 24-bp deletions frequency, that as we have seen, are supported by MH 
(Figure 21 C). A closer look at the NGS data regarding the PRKDC deficient background 
shows a significant increase by 14% of the 2 bp length insertion frequency (Figure 21 D). 
Simultaneously the frequency of 11-, and 24-bp deletions is significantly increased since in 
most cases they are supported by MH of 2-8 bp length.  
Moreover, NGS data shows that in a PARP1 deficient background, the frequency of 2-, 11-, 
and 24-bp deletions that are supported by microhomologies is decreased. Our findings 
demonstrate how alt-EJ is involved during the DNA repair process (Figure 21 D) and are 
consistent with the current literature. Collectively our data suggest that in the absence of major 
components of c-NHEJ then a convergent pathway (alt-EJ) takes over the DNA repair process 
by increasing the rates of MH. 
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Figure 21: Mapping the impact of DNA repair deficiency by sequencing. (A) Representative flow cytometry 
analysis plot of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA targeting the eGFP coding 
sequence in PRKDC and PARP1 KO cells. Numbers inside plots indicate percentages of live cells. Axes report 
relative fluorescence intensity in arbitrary units. (B) Quantification of flow cytometry analysis for HEK293CAT-R 
deficient cells. Data presented in box and whiskers (min to max) with a minimum of 7 biological replicates. A 
standard student t-test is used to calculate the P-values between untreated and treated samples. (C) Deep targeted 
next-generation sequencing to detect InDels at the targeted site from genomic DNA harvested 72 h after 
transfection in PRKDC and PARP1 KO cells. (D) Profile of the various bp length types in WT, PRKDC and PARP1 
KO cells. 
The impact of genetic background in DNA repair choice 
Next, we wanted to assess how the genetic background (PRKDC-/- and PARP1-/-) influences 
the actions of 13 prominent DNA repair genes (ATM, ATR, BRCA1, BRCA2, CHK1, NHEJ1, 
PARP1, PARP2, PARP3, POLQ, PRKDC, RAD51B, XRCC4) involved in end-protection and 
end-resection pathways.  
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Figure 22: The impact of genetic background in DNA repair choice. (A) Schematic workflow of the mini siRNA 
screen. (B) Gene expression levels measured by RT-qPCR three days post-transfection with siRNA. Cook’s 
distance bar plots in a (C) PRKDC, and (D) PARP1 deficient background. Representative flow cytometry analysis 
plots of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA targeting the eGFP sequence in (E) WT, 
(G) PRKDC, and (I) PARP1 KO cells. Numbers inside plots indicate percentages of live cells. Axes report relative 
fluorescence intensity in arbitrary units. Box and whisker plots (min to max) of flow cytometry analysis for 
HEK293CAT-R KD cells are shown in (F) WT, (H) PRKDC, (G) PARP1 background. Data presented with 16 biological 
replicates.  
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Therefore, we used a small-scale arrayed RNAi screen, with every gene to be targeted by a set 
of 2 independent siRNAs. In total, we transfected 28 siRNAs, including negative controls to 
the cells by reverse liquid transfection and three days post-transfection, we delivered the gRNA 
targeting the eGFP sequence. At day 6, we assessed the eGFP and mCherry ratios by high-
throughput flow cytometry, and we calculated Z scores of all three populations per gene based 
on non-targeting (scrambled) controls (Figure 22 A). The level of KD efficiency is controlled 
by measuring the RNA levels of the transfected cells three days post-transfection by RT-qPCR 
(Figure 22 B).  In order to detect the genes with the highest impact, we used a standard outlier 
diagnostic tool (Cook’s distance) for each of the three genetic backgrounds (WT, PRKDC-/-, 
and PARP1-/-) (Figure 22 C, D).  
In a PRKDC KO background, we observe a change in the DDR response of the tested genes 
mostly in the frequency of large deletions. In this background, small InDels are a minor 
population that presumably points to repair by alt-EJ. In contrast, the PARP1 KO background 
deregulates more genes, and especially genes that are involved in end-resection pathways, such 
as BRCA1, ATR, and RAD51. The impact of PRKDC loss is so prominent that none of the 
tested genes were able to influence significantly the small InDel phenotype (Figure 22 E). The 
results show that in a PRKDC deficiency, the effect of BRCA1 is minimized, implying that 
BRCA1 is no longer in the driving force of dictating the pathway choice since the burden of 
repair relies solely on end-resection pathways.  
In the PARP1 deficient background, the most affected genes are RAD51B, BRCA1, and ATR; 
with all three to be implicated in end-resection mechanisms. In PARP1_RAD51B deficient 
cells, the error-free repair is favored substantially with the simultaneous reduction of small 
InDels and large deletions. Similar results are observed also in the PARP1_BRCA1 and 
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PARP1_ATR deficient cells (Figure 22 E,F,G). Interestingly, cell viability remains intact 
throughout the seven days of analysis, with a minor reduction in the RAD51 deficient cells. 
Recent studies have shown that in a PARP1 KO background, there is an increase in Rad51 foci 
formation (Ronson et al. 2018), suggesting that RAD51 might have a progressive role in 
dictating the fate of end-resection. Our results indicate a direct or indirect PARP1 association 
to RAD51 in restoring HR (Figure 22 I). In addition, previous studies have shown that in the 
absence of PARP1, Ku70/Ku80 dimer, 53BP1, and RIF1 are no longer localized to the DNA 
damage site effectively (Ray Chaudhuri and Nussenzweig 2017). Therefore, the presence or 
absence of BRCA1, which acts as the opposing side to maintain the balance of end-protection 
vs. end-resection, might not be so crucial in a PARP1 deficiency. A remark that can be 
highlighted from our data, since the loss of BRCA1 in a PAPR1 deficient background does not 
affect the DNA repair choice as much as it did in a wild-type background (Figure 22 I). 
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Chapter 6 
Drug compound screening 
Using genetic deficiencies in key molecules involved in DNA DSB repair, we established that 
CAT-R could dynamically respond to changing conditions in DSB repair choice. This chapter 
describes how CAT-R can be used to assess the level of engagement of a drug compound to 
DNA repair choice. Since the high efficiency of DSB induction in our system potentially 
allows us to detect even minor changes in DSB repair choice, we tested whether we can utilize 
this fluorescent reporter as a platform to assess the in vitro potencies of different DDR inhibitor 
classes. To this end, we selectively targeted the key enzymes of DNA repair that are in 
preclinical and clinical trials in a concentration-dependent manner. We first screened 13  
inhibitors that target three significant classes of PI3 Kinase related protein kinase (PI3KK) 
family members that are involved in DNA damage signaling and repair: DNA-PK, ATM, ATR 
as well as the CHK1 and Wee1 kinase and analyzed their response by high-throughput flow 
cytometry. Next, we expanded our screening approach to 11 additional compounds targeting 
histone deacetylase (HDAC) and poly (ADP-ribose) polymerase (PARP) inhibitors. In this 
chapter, we present how CAT-R can be used as a platform to screen small pharmacological 
compounds. 
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Table 1: List of small pharmacological compounds used in this study 
Compound 
name 
Target Cancer target type/ Indications 
Development 
stage 
Company 
KU-0060648 DNA-PK Ν/Α Phase I KuDOS Ltd 
M3814 DNA-PK 
Rectal cancer, advanced solid 
tumors 
Phase I/II Merck KGaA 
NU7026 DNA-PK Ν/Α N/A KuDOS Ltd 
NU7441 DNA-PK Ν/Α N/A KuDOS Ltd 
AZD0156 ATM Advanced Solid Tumors Phase I AstraZeneca plc 
KU-55933 ATM N/A N/A KuDOS Ltd 
KU-60019 ATM N/A N/A KuDOS Ltd 
M3541 ATM Solid Tumors Phase I Merck KGaA 
AZD6738 ATR Small Cell Lung Cancer  Phase II AstraZeneca 
M1774 ATR Ν/Α N/A Merck KGaA 
M4344 ATR Advanced solid tumors Phase I Merck KGaA 
M6620 ATR Advanced solid tumors Phase I Merck KGaA 
GDC-0425 CHK1 Refractory Solid Tumors Phase I Genetech Inc. 
AZD1775 Wee1 
Adenocarcinoma of the 
Pancreas 
Phase II AstraZeneca plc 
Talazoparib PARP 
Locally Advanced Breast 
Cancer, Metastatic Breast 
Cancer  
Phase III Biomarin/Pfizer Inc. 
Niraparib PARP 
Fallopian Tube Cancer, Ovarian 
Epithelial Cancer, Primary 
Peritoneal Cancer 
Phase III Tesaro/Merck & Co. 
Rucaparib PARP Advanced Ovarian Cancer Phase II Clovis/Pfizer 
Olaparib PARP 
Fallopian Tube Cancer, 
Metastatic Breast Cancer 
(MBC), Ovarian Epithelial 
Cancer, Refractory Advanced 
Ovarian Cancer 
FDA approved 
KuDOS/AstraZeneca 
plc 
Veliparib PARP Ovarian Cancer Phase II 
Abbott 
Laboratories/ 
AbbVie 
Iniparib PARP Solid Tumors Phase III Sanofi S.A. 
INO-1001 PARP Heart Diseases Phase II Inotek/Genetech 
ATM, ataxia telangiectasia mutated; ATR, AT and rad-3 related; CHK1, checkpoint kinase 1; 
DNA-PK, DNA-dependent protein kinase; PARP, poly adenosine diphosphate-ribose 
polymerase. 
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6.1. DNA repair & small pharmacological compounds 
We used a selective DNA-activated protein kinase catalytic subunit (DNA-PKcs) inhibitor  
KU-0060648 (500 nM), a potent ataxia telangiectasia mutated (ATM) inhibitor AZD0156  
(500 nM), and an ataxia telangiectasia and Rad3-related (ATR) inhibitor M4344 (100 nM) with 
our reporter to trace the impact on DNA repair choice after a Cas9-mediated DSB. From our 
data it is clear that inhibition of DNA-PKcs and ATM reduces the frequency of small InDels 
on average by 28% and 34% respectively (Figure 23 A). On the other hand, ATR inhibition 
increases the frequency of small InDels by 5%, suggesting an opposing role in DSB repair 
choice. 
 
Figure 23: A platform to screen important DDR inhibitors. (A) Representative flow cytometry analysis plots of 
HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA in the presence of the inhibitors: DNA-PKi (KU-
0060648), ATMi (AZD0156), ATRi (M4344) and WEE1i (AZD1775). Numbers shown inside plots indicate 
percentages of live cells. Axes report relative fluorescence intensity in arbitrary units. (B) Workflow schematic of 
the small pharmacological compound screen. HEK293CAT-R cells induced with doxycycline (1 μg/ml) are seeded 
on a 96-well plate, and 24 h later, the cell culture medium is supplemented with the drug compounds. An hour 
afterward, the synthetic gRNA complex is transfected to the cells. Three days post-transfection, cells are analyzed 
in a high-throughput flow cytometer. 
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We coupled CAT-R with high-throughput flow cytometry to provide for the first time a head-
to-head comparison of 24 pharmacological compounds, using CAT-R as a platform to screen 
small pharmacological compounds (Figure 23 B). Cells were seeded on a 96-well plate and 
24 h later the cell culture medium was supplemented with the appropriate drug compound. An 
hour afterward, the synthetic gRNA complex targeting the eGFP sequence was transfected to 
the cells. Three days post-transfection, cells were analyzed in a high-throughput flow 
cytometer. 
DNA-PKi acts in favor of end-resection 
We compared four different DNA-PKcs compounds that inhibit the major kinase responsible 
for the cellular c-NHEJ activity and DSB repair (Adamo et al. 2010) at 8 different 
concentrations from 1–500 nM. On average, the reduction of small InDel formation was 19% 
(±4) with the simultaneous increase of large deletions by 18% (±4) at 250 nM, coming in 
agreement with the phenotype we observed with the knock-out of PRKDC (Figure 24 A). 
These results follow the fact that in the presence of DNA-PKcs, the DSBs are repaired by the 
c-NHEJ pathway, which contributes to the mCherry+/GFP- population.  
Interestingly, there were no significant differences in DNA repair choice when the small-
molecule inhibitor NU7026 was tested at concentrations lower than 500 nM. However, an 
improved analog of NU7026, the NU7441, performed slightly better by reducing the frequency 
of small InDels by 8% (±0.7) and increasing the large deletions formation by 5% (±0.5) at 
concentrations higher than 250 nM (Figure 24 A). However, when the DNA-PKcs inhibitor 
KU-0060648 and M3814 were compared, there was no significant difference. The results show 
that both compounds have a similar pharmacodynamic profile, acting at concentrations as early 
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as at 50 nM by reducing the formation of small InDels on average by 18% (±4) and increasing 
large deletions by 19% (±4) (Figure 24 A).  
 
Figure 24: Effect of DNA-PK inhibitors in DNA repair choice. (A) Scatter plots (mean and SD error) of flow 
cytometry analysis for HEK293CAT-R cells are showing the effect of DNA-PKcs inhibitors on the DNA repair choice, 
with sample size to be annotated. Additionally, a scatter plot (B) serves as a control to lipid-mediation in which a 
siRNA against eGFP is transfected in the presence of the inhibitors. The sample size is annotated, and the values 
are normalized to untreated control. (C) Cell cycle profile of DNA-PKcs inhibitors upon three days of treatment. (D) 
Cell viability assay in HEK293CAT-R in the presence of DNA-PKcs inhibitors. The analysis is performed three days 
after treatment. 
Meanwhile, we investigated whether compounds as standalone drugs, affect cell proliferation 
or have a prominent effect on cell cycle or transfection. We report that neither of the 
compounds exhibits any cell cycle or transfection de-regulation (Figure 24 B,C). However, 
we report that at concentrations between 200-500 nM, KU-0060648 slows down cell 
proliferation approximately by 50% during three days of incubation (Figure 24 D), findings 
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that are supported by other studies too (Chen et al. 2016). Overall, inhibition of DNA-PKcs acts 
in favor of end-resection by strongly decreasing the frequency of small InDels and increasing 
the formation of large deletions as well as the error-free repair. 
ATMi phenocopies DNA-PKi profile 
We wondered how ATM inhibition could affect DNA repair choice. To answer this question, 
we selected a series of ATM inhibitors to screen for their in-vitro influence in the choice of 
DNA repair at concentrations from 1–500 nM. We report several similarities with DNA-PKcs 
inhibition profile since the DNA repair choice after ATM inhibition leads to increased rates of 
large deletions by 24% (±2.6) and simultaneously to the reduction of small InDels formation 
by 26% (±2.8) at 250 nM (Figure 25 A). 
It is clear that the AZD0156 compound achieves a robust change to the phenotype at 
concentrations as low as 5 nM, consistent with it is in vivo reported potency (Tse, Carvajal, 
and Schwartz 2007). Additional selective ATM inhibitor compounds such as M3541, and  
KU-60019, exhibit a similar profile by reducing small InDels formation and increasing large 
deletions on average by 25% (±2.6) at 200 nM (Figure 25 A). The compound KU-55933 
appears to have a very week potency at concentrations lower than 500 nM. Additionally, we 
investigated the cell growth inhibition of individual compounds, and the findings indicate that 
only AZD0156 stalls cell growth almost by 50% at concentrations higher than 200 nM after 
three days of incubation (Figure 25 B,C). The most potent ATM inhibitor AZD0156 slightly 
increases the time cells spent in S phase (Figure 25 D), however, this effect is not substantial 
enough to explain the drastic decrease in the formation of small InDels observed upon ATM 
inhibition at similar concentrations.  
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Figure 25: Effect of ATM inhibitors in DNA repair choice. (A) Scatter plots (mean and SD error) of flow 
cytometry analysis for HEK293CAT-R cells are showing the effect of ATM inhibitors on the DNA repair choice, with 
sample size to be annotated. (B) Cell viability assay in HEK293CAT-R in the presence of ATM inhibitors. The analysis 
is performed three days after treatment. Additionally, a scatter plot (C) serves as a control to lipid-mediation in 
which a siRNA against eGFP is transfected in the presence of the inhibitors. The sample size is annotated, and 
the values are normalized to untreated control. (D) Cell cycle profile of ATM inhibitors upon three days of treatment. 
(E) Effect of dual ATM and DNA-PK inhibition on DNA repair choice. Representative flow cytometry analysis plot 
of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA targeting the eGFP HEK293CAT-R. Numbers 
shown inside plots indicate percentages of live cells. Axes report relative fluorescence intensity in arbitrary units. 
(F) Box and whiskers plot (min to max) of flow cytometry analysis for HEK293CAT-R cells in the presence of ATM 
and DNA-PK inhibitors. Data presented with a minimum of 6 biological replicates. 
We also tested whether inhibition of ATM has off-target effects and directly impacts on  
DNA-PKcs activity. To this end, we compared the effect of DNA-PKcs inhibition, alone to 
combined inhibition of ATM and DNA-PK (Figure 25 E). Using 50 nM concentration of 
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DNA-PKcs inhibitor M3814, we have observed a 6.6% (±1.1) reduction in the formation of 
small InDels. This effect was exacerbated by the combined inhibition of ATM and DNA-PKcs, 
leading to an 11% (±0.9) decrease in the formation of small InDels, arguing that ATM acts as 
the first responder at the ATM-DNA-PKcs signaling cascade (Figure 25 E). 
Targeting the ATR-CHK1-WEE1 axis creates a dependency on 
end-protection  
A large body of preclinical data supports the further development of ATR, CHK1, and Wee1 
inhibitors that are currently being investigated in clinical trials as monotherapy or in 
combination with standard of care agents. Given their standing to clinical research a series of 
ATR inhibitors were used to evaluate their influence on DNA repair choice at concentrations 
from 1–100 nM. 
The primary phenotype of the ATR inhibition was the reduction of large deletions and 
simultaneous increase of small InDels frequency on average by 3% (±2) at 100 nM (Figure 26 
A). A pair of highly selective and potent small-molecule inhibitors of ATR, M4344, formerly 
known as VX803 & AZD6738 were used with CAT-R reporter assay. M4344 showed the most 
robust phenotype by influencing predominantly the end-resection pathways. It reduced the 
frequency of large deletions by 10% (±4.2) at 50 nM and channeled the DNA repair choice 
towards the formation of small InDels (Figure 26 A). The most surprising finding was the 
profile of the highly selective and potent ATR kinase inhibitor, AZD6738. The profile of 
AZD6738 differed among the other ATR compounds by reducing the formation of small 
InDels and increasing the formation of large deletions by 2% (±0.7) at 50 nM. 
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Figure 26: Effect of ATR-CHK1 inhibitors in DNA repair choice. Scatter plots (mean and SD error) of flow 
cytometry analysis for HEK293CAT-R cells are showing the effect of (A) ATR, (B) CHK1-WEE1 inhibitors on the 
DNA repair choice, with sample size to be annotated. Cell viability assay in HEK293CAT-R in the presence of (C) 
ATR, (E) CHK1-WEE1 inhibitors. The analysis is performed three days after treatment. Additionally, a scatter plot 
(E, F) serves as a control to lipid-mediation in which a siRNA against eGFP is transfected in the presence of the 
inhibitors. The sample size is annotated, and the values are normalized to untreated control. (G) Cell cycle profile 
of DNA-PKcs inhibitors upon three days of treatment. 
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Additionally, we investigated the cell growth inhibition of individual compounds, with M4344 
and M6620 compounds to show signs of severe cell toxicity at concentrations higher than  
50 nM that can reach up to 75% in 100 nM concentration. On the contrary AZD6738 compound 
exhibits no signs of cell proliferation stalling or any type of cytotoxic effects (Figure 26 B). 
We also evaluated the inhibition of CHK1, which is a downstream target of ATR, with a 
selective compound (GDC-0425). The profile of GDC-0425 showed a similar phenotype with 
the ATR inhibitors since it reduces the frequency of large deletions and increases the formation 
of small InDels on average by 8% (±2) at 100 nM (Figure 26 D). In addition, we evaluated 
Wee1 inhibition, which is an inhibitor of CDK1 and plays a role in the ATR-CHK1 pathway 
in multiple ways. We used a potent and selective small-molecule inhibitor of Wee1, the 
AZD1775 compound (formerly known as MK-1775). Inhibition of Wee1 with AZD1775 
showed a similar phenotype to ATR-CHK1 inhibition. Collectively our data suggest that by 
targeting the ATR-CHK1-Wee1 axis the DNA repair is channeled to end-protection pathways. 
HDAC inhibitors in DNA repair choice 
We tested four broad-spectrum histone deacetylase (HDAC) inhibitors to understand their 
effect on DDR choice. HDAC proteins remove acetyl groups from a lysine amino acid of a 
histone allowing them to wrap the DNA more tightly. Therefore, HDAC inhibitors promote 
the acetylation of histones potentially favoring end-resection based mechanisms. In contrast 
to what was expected, all compounds show a similar profile by increasing the formation of 
small InDels on average by 7.6% (±5.7) at 1 μM concentration and a simultaneous decrease 
in large deletions (Figure 27 A). The most substantial effect on DNA repair choice belongs 
to Abexinostat, and Panobinostat, a pair of pan-spectrum HDAC inhibitors. Abexinostat 
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increases the formation of small InDels on average by 10% (±2.3) at 500 nM, whereas 
Panobinostat shows a similar effect on average by 6.8% (±2.3) at a lower concentration (20 
nM) (Figure 27 B). We also used another well-studied pan-spectrum HDAC inhibitor, 
Vorinostat (or else known as SAHA), in a concentration from 100-1000 nM but we were not 
able to detect a prominent swift in the DNA repair choice at those concentrations. From our 
data, we can suggest that Panobinostat has a higher in vitro drug potency than Abexinostat 
and other HDAC inhibitors.
 
Figure 27: Comparing the in vitro activity of HDAC inhibitors. (A) Representative flow cytometry analysis plots 
of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA in the presence of the inhibitor HDAC 
(Panobinostat). Numbers shown inside plots indicate percentages of live cells. Axes report relative fluorescence 
intensity in arbitrary units. (B) Scatter plots (mean and SD error) of flow cytometry analysis for HEK293CAT-R cells 
are showing the effect of HDAC inhibitors on the DNA repair choice, with sample size to be annotated. (C) Cell 
viability assay in HEK293CAT-R in the presence of HDAC inhibitors. The analysis is performed three days after 
treatment. Additionally, a scatter plot (D) serves as a control to lipid-mediation in which a siRNA against eGFP is 
transfected in the presence of the inhibitors. The sample size is annotated, and the values are normalized to 
untreated control. (E) Effect of HDAC inhibitors on the cell cycle profile. 
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Furthermore, we evaluated the effect of HDAC inhibitors on cell viability. In general 
HEK293CAT-R cells were affected by HDAC inhibitors especially at high concentrations where 
cell viability was reduced up to 50% (Figure 27 C). Furthermore, to better understand the 
DNA repair outcome, we examined the effect of HDAC inhibition on cell cycle profile. Both 
Abexinostat and Panobinostat compounds affect the cell cycle, by increasing the time cells 
spent in G1 phase (Figure 27 E). This difference might be enough to explain the increase in 
the formation of small InDels, attributing the phenotype of HDACi mostly to the cell cycle 
stalling and not to DDR manipulation. 
PARP inhibitors in DNA repair choice 
Inhibition of poly (ADP-ribose) polymerase (PARP) shows promising results in preclinical 
studies and clinical trials. For some cancer types, PARPi is used either as a monotherapy or in 
combination therapy. In this study, we compared 7 PARP inhibitors sharing a similar 
architecture and evaluated their effect on DNA repair choice at concentrations from 0.5 nM up 
until 3 μM. In addition to our high throughput flow cytometry-based assessment of repair 
choices, we also evaluated the toxicity of each compound based on ATP measurements. The 
general phenotype of PARP inhibitors was the reduction of small InDels formation and the 
increase of large deletions on average by 4% (±1.6) at 50 nM (Figure 28 A). These results 
agree well with the idea that in the presence of PARP, the DSBs are repaired by the alternative 
EJ pathway, which contributes to the mCherry+/GFP- population.  
Comparing the potency of all these PARP inhibitors, consistent with the literature, we found 
that Talazoparib performs much better than other inhibitors even at concentrations as low as 
10 nM. Talazoparib reduces the formation of small InDels by 5% (±2.4) and slightly increases 
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the formation of large deletions at 50 nM (Figure 28 B). Increasing concentrations of 
Talazoparib higher than 50 nM exhibit a different phenotype, possibly due to the toxic effects 
of the drug in this cell line (Figure 28 C). Unexpectedly, in addition to the reduction of cell 
proliferation, we noted that at concentrations higher than 50 nM, Talazoparib also blocks lipid-
mediated transfection; thus, they are excluded from our analyses (Figure 28 D).  
The next group of inhibitors that are slightly less efficient than Talazoparib is Niraparib, 
Rucaparib, and Olaparib. At 200 nM concentration, the average reduction of these three 
compounds in the formation of small InDels is 4% (±1.7). These effects were exacerbated 
when we increased the compound concentration to 1 μM.  
Interestingly, when we tested Veliparib, Iniparib, and INO-1001, a group of compounds that 
are among the first PARP inhibitors that were later shown not to possess any PARP-trapping 
activity, none of these three compounds exhibited any prominent effect in the repair of Cas9-
induced DSB. Moreover, this group of compounds has a positive effect on cell proliferation at 
concentrations higher than 200 nM potentially due to the off-target drug effects on metabolic 
pathways (Figure 28 E).  
Altogether these results suggest that CAT-R can measure not only differences in compound 
activities that directly affect DSB repair such as DNA-PK but also PARP trapping activity and 
can be used as a screening platform for a rapid in vitro assessment of DDR compound 
efficiencies. 
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Figure 28: Comparing the in vitro activity of clinical PARP inhibitors. (A) Representative flow cytometry 
analysis plots of HEK293CAT-R cells 72 h post-transfection with the synthetic gRNA in the presence of the inhibitor 
PARP (Niraparib). Numbers shown inside plots indicate percentages of live cells. Axes report relative fluorescence 
intensity in arbitrary units. (B) Scatter plots (mean and SD error) of flow cytometry analysis for HEK293CAT-R cells 
are showing the effect of PARP inhibitors on the DNA repair choice, with sample size to be annotated.  
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(C) Cell viability assay in HEK293CAT-R in the presence of PARP inhibitors. The analysis is performed three days 
after treatment. Additionally, a scatter plot (D) serves as a control to lipid-mediation in which a siRNA against eGFP 
is transfected in the presence of the inhibitors. The sample size is annotated, and the values are normalized to 
untreated control. (E) Effect of PARP inhibitors on cell cycle profile. 
6.2. Predicting drug-likeness response with a machine 
learning model 
Thanks to the high efficiency of the CAT-R system, even small differences in DSB repair 
choices can be evaluated, and different classes of compounds can be identified.  To adapt this 
system for potential compound screening purposes, I collaborated with Dr. Salvatore Benfatto 
to build a machine-learning-based model that can predict the type of compounds based on their 
phenotype from the CAT-R assay.  
 
Figure 29: Machine learning model to predict drug-likeness response to DSB: Four-dot plots are showing the 
accuracy of the Random-Forest generated model for the different classes of compounds. TN: True Negative, FP: 
False Positive, TP: True Positive, and FN: False Negative. 
A random forest (RF) model is generated to predict the classes of the compounds starting from 
the data in output from the CAT-R assay. A pre-filtering step is required to remove samples 
that do not show a significant change from the initial DSB phenotype. Of the 2624 initial 
samples, 434 are filtered out since they do not show significant changes from the control 
phenotype generated by the gRNA targeting the eGFP sequence without any treatment. From 
the remaining data, 80% was used to train an RF model, and the other 20% was used as a test 
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set to assess the model performance (Table 2). The final RF model showed an overall accuracy 
of 83%, and the statistical measures for almost all the compound classes were generally high 
(Figure 29). Notably, the model showed excellent ability to discriminate against the true 
negatives (high specificity) and to predict the classes of the DNA-PKi, ATMi, ATRi, and 
PARPi compounds in the test set correctly. Moreover, some ATMi and DNA-PKi compounds 
showed very similar phenotypes; however, we were able to predict accurately the right class 
the 68% and 65% of the times, respectively (Figure 29, Table 2). Overall the RF model 
exhibited great performances suggesting its potential future employment to predict the classes 
of unknown compounds, in terms of phenotype similarity with the trained classes, starting from 
the data in output from the CAT-R assay. 
Table 2: Random Forest model analysis. 
RF-based classification models 
Class 
Sample 
size (n) 
Sensitivity% 
Specificity 
(%) 
PPV (%) NPV (%) 
Accuracy 
(%) 
DNA-PKi 190 65% 95% 60% 96% 95% 
ATMi 259 68% 97% 76% 95% 96% 
ATRi 343 89% 96% 82% 98% 96% 
HDACi 132 95% 99% 96% 99% 99% 
PARPi 589 85% 94% 85% 94% 95% 
N = 2190, CI: confidence intervals, PPV: Positive predictive value, NPV: Negative predictive 
value. 
Validation data set - Confusion matrix 
Prediction Total DNA-PKi ATMi ATRi HDACi PARPi 
DNA-PKi 37 25 11 1 0 0 
ATMi 46 11 35 0 0 0 
ATRi 71 0 4 61 0 6 
HDACi 25 0 0 0 25 0 
PARPi 107 2 0 5 0 100 
Accuracy: 83%, 95% CI: (79%, 86%), Kappa: 79% 
ATM, ataxia telangiectasia mutated; ATR, AT and rad-3 related; CHK1, checkpoint kinase 1; 
DNA-PK, DNA-dependent protein kinase; HDAC. Histone deacetylase; PARP, poly adenosine 
diphosphate-ribose polymerase. 
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Chapter 7 
CRISPR/Cas9 arrayed genetic screen  
At present, little is known about the interplay of the DNA repair pathways during the decision 
of DNA repair choice. In the previous chapter, we established that CAT-R can respond to even 
minor genetic deficiencies during the DNA repair choice. In this chapter, we explore the effects 
of individual DNA repair genes on DSB repair and identify the major regulators of Cas9-
mediated double-strand break repair.  
7.1. An arrayed screen for regulators of DSB repair  
The DNA damage response is a multifactorial process; therefore, we designed an arrayed 
CRISPR/gRNA library targeting 417 genes involved in DNA repair to investigate the effects 
of individual components during the DNA DSB repair. Each gene is targeted by two individual 
gRNAs, and in total, we transfected 932 gRNAs, including four positive (POLR2A) and six 
negative (Scrambled, non-targeting gRNA) controls to the cells by solid-phase transfection. 
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Three days post-transfection, we transfected the gRNA targeting eGFP, and three days later 
assessed the eGFP and mCherry ratios by high throughput flow cytometry. We calculated Z 
scores of all three populations based on non-targeting (scrambled) controls. We removed 48 
genes whose KO resulted in a dramatic decrease in viability after five days from the subsequent 
analyses (Figure 30 A). Among 369 genes after this initial filtering step, we formed clusters 
based on the three populations applying a K-Means clustering method. Estimating the optimal 
number of clusters to be 5, we then performed pathway enrichment analysis on these 5 clusters. 
A scatter diagram depicts the landscape of the fundamental mechanisms that regulate and 
promote the DNA repair choice after a Cas9-mediated DSB (Figure 30 B). As expected, c-
NHEJ was enriched in the cluster with low Z scores of small InDels and high Z scores of large 
deletions, consistent with their phenotype of reduced formation of small InDels. In this cluster, 
loss-of-function of essential genes for end-protection, such as RNF168, TP53BP1, ATM, SETX, 
PRKDC, XRCC4 displayed the most considerable differences as compared to the scrambled 
(Figure 30 B). On the other hand, loss-of-function of essential genes for end-resection, such 
as the FA components BRCA1, USP1, COPS4, BARD1 significantly increased the formation 
of small InDels and reduced the formation of large deletions. In addition, loss of HRR 
components reduces the formation of large deletions primarily and channels the repair to small 
InDels formation. Several HRR components are positively affecting the formation of small or 
large InDels, suggesting that in the absence of these genes, a more efficient KO can take place 
(Figure 30 C). 
In order to identify the most active influencers of Cas9-mediated DSB repair, we used a 
standard outlier diagnostic tool (Cook’s distance) for each of the 369 genes (Figure 30 D). We 
found 25 genes that are identified as outliers.  
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Figure 30: The landscape of Cas9-mediated double-strand break repair. (A) Workflow schematic of the 
CRISPR/gRNA genetic screen. In total, 417 genes are targeted with two different gRNA sequences. HEK293CAT-R 
cells are induced with doxycycline (1 μg/ml) and then transfected with the solid-phase methodology in pre-coated 
96-well plates to deliver the gRNA arrayed library. At 96 h, the cells are transfected with the gRNA: eGFP and at 
7-day analyzed in a high-throughput flow cytometer. Data points are averaged, and the Z-score values are 
calculated per 96-well plate. (B) A scatter diagram showing the effect of 417 genes upon Cas9-mediated DSB. In 
the x-axis, the regulation of small InDels and in the y-axis, the regulation of the large InDels are presented. K-
Means clustering is applied with the “elbow point” to be 6 clusters. Pathway enrichment analysis of the 6 clusters 
reveals the implication of end-resection, end-protection, and nucleotide excision repair (NER) related genes. (C) 
Individual k-Means clusters profile in terms of DNA DSB repair choice with the use of the CAT-R system. Each dot 
represents a gene. (D) Cook’s distance bar plot identifies genes with the most robust phenotype upon Cas9-
mediated DSB. Box and whiskers plots (min to max) of flow cytometry analysis for the HEK293CAT-R cells are shown 
in (E), and (F). Values are normalized to control gRNA: eGFP. 
Consistent with our clustering approach, we identified several known genes of the c-NHEJ 
(such as RNF168 and TP53) to be essential for decreasing the rate of small InDels formation 
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and increasing the rate of large deletions along with potentially new regulators of this process 
such as TTI1 and DDX11 (Figure 30 E). TTI1 was identified from a genetic screen as a part 
of a triple complex and is required for DNA damage signaling to stabilize ATM and ATR 
(Hurov, Cotta-Ramusino, and Elledge 2010). It controls the G2/M and Intra S-phase DNA 
damage checkpoints by regulating PIKK proteins (Ciccia and Elledge 2010). Here we confirm 
these discoveries and suggest that TTI1 acts in favor of the end-protection mechanism to an 
equal extent as the loss of ATM function. 
Furthermore, DDX11 (also known as ChlR1) is a DEAH-box DNA helicase essential in DNA 
repair, chromosome structure, and genome integrity (Abe et al. 2016). It has been shown that 
DDX11 is vital to unwind the DNA with a 5’ to 3’ directionality, behaving similar to ERCC2 
(XPD) (Bharti et al. 2014). Its action creates a 5’ flap structure which resembles an 
intermediate step of the lagging strand synthesis and therefore DNA repair pathways such as 
base excision repair is required. Pearl et al. characterize DDX11 as a gene with probable DDR 
role (Pearl et al. 2015), and our data suggest that it is a strong influencer of small InDels 
formation (Figure 30 E). 
Overall, loss of end-protection components decreases the frequency of small InDels, whereas 
loss of end-resection components increases the rate of small InDels (Figure 30 E, F). In a 
recent study, it was shown that multiple FA components were important for a Cas9-mediated 
single-strand template repair (SSTR) but not for c-NHEJ (Richardson et al. 2018). 
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7.2. Involvement of Nucleotide Excision Repair in Double-
Strand Break  
Interestingly, these analyses also revealed that individual NER components (such as RBX1, 
RAD23A, DDB1, ERCC5, ERCC8, and ERCC3) increased the “error-free” population while 
reducing both small InDels and large deletions. These results suggested that targeting these 
genes may increase the efficiency of error-free repair in cells upon Cas9-mediated breaks. 
We tested the effect of individual NER components such as ERCC5 (XPG), ERCC8 and 
ERCC3 (XPB) in regulating SSTR (Figure 31 A). To this end, we first transiently transfected 
the HEK293CAT-R cells with gRNAs targeting the ERCC5 (XPG), ERCC8 and ERCC3 (XPB), 
along with PRKDC that was previously shown to increase the rate of knock-ins.  
 
Figure 31: Deficiency in NER components increases Knock-in efficiency. (A) Box and whiskers plots (min to 
max) of flow cytometry analysis for the HEK293CAT-R cells. Values are normalized to control gRNA: eGFP. (B) A 
box and whiskers plot (min to max) showing the conversion of GFP to BFP with the use of an asymmetric ssODN 
template. In the absence of PRKDC, the single-strand template repair (SSTR) is increased. Once essential NER 
genes are a knock-out, the SSTR is further increased. (C) The knock-out expression levels 72 h after transfection 
is validated by RT-qPCR. 
We then transfected the gRNA targeting eGFP together with a ssODN serving as a template 
for GFP to BFP conversion. The efficiency of a successful conversion in normal  
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HEK293CAT-R was, on average, 2.5% (±1.5). In the case of a genetic depletion such as PRKDC, 
the conversion efficiency was increased to 3.1% (±0.7) (Figure 31 B), consistent with 
previously reported effects of PRKDC KO in increasing the knock-in efficiency by blocking 
the c-NHEJ (Certo et al. 2011). Interestingly, when we target the NER genes that regulate the 
3’ flap removal such as ERCC3, ERCC5, ERCC8, we also observed an increase in the knock-
in efficiency of up to 4.5% (±0.1). The level of KO efficiency is controlled by measuring the 
RNA levels of the transfected cells three days post-transfection by quantitative polymerase 
chain reaction (RT-qPCR) (Figure 31 C). Overall, the results suggest that removal of 5’ to 3’ 
flaps by the NER pathway is important for mediating SSTR and thus suggest an alternative 
way for increasing the rate of knock-ins in cell lines. 
7.3. A proposed mechanism of Cas9-mediated DSB repair 
choice 
Based on our results and previous reports, we propose a sequence of events that can occur upon 
a CRISPR/Cas9 mediated DSB (Figure 32). Once the Cas9 endonuclease binds to its DNA 
target sequence, it undergoes a massive conformational change of ~140o (anti-clock-wise) that 
enables the dual cleavage of the loci (Zhu et al. 2019). An electron microscopy study has shown 
that the distal DNA end to the PAM sequence is released, whereas, in the proximal side, the 
Cas9 complex remains bound (M. Shibata et al. 2017). End-protection proteins will likely bind 
immediately to the released DNA strand stabilizing the ends and avoiding any chromosomal 
loss. Therefore, we hypothesize that it is less likely to have end-resection at the distal DNA 
side. On the other DNA side more and more studies so that a 5’ to 3’ flap will be generated 
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during the Cas9 cleavage process (Janssen et al. 2019), (Richardson, Ray, Dewitt, et al. 2016). 
Generally, 5’ to 3’ flaps can be removed by the NER mechanism. Here, we show that in the 
absence of crucial NER genes, most likely the 5’ to 3’ flap cannot be removed efficiently 
increasing the chances of a successful KI via SSTA/HDR event. 
 
Figure 32: Proposed mechanism of Cas9-mediated DSB repair choice. Once a Cas9-mediated DSB occurs, 
end-protection mechanisms or alt-EJ will act to favor a quick ligation and thus form small InDels. If the damage is 
not repaired, then end-resection mechanisms will start resecting the region leading to large InDels. Due to the 
nature of Cas9-mediated DSB, a 3’ flap is created and possibly it is removed with the help of NER components. If 
this 3’ flap is not removed, then it favors a more efficient knock-in. 
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Chapter 8 
Identifying novel PARP interactions 
The impact of the genetic background in DNA repair choice is mostly understudied. In the 
previous chapters we showed how the loss of PARP1 deregulates several components of the 
DNA repair choice, and we highlighted the association of PARP1 and RAD51 in restoring the 
phenotype by increasing the rates of error-free repair. 
In this chapter, we are using a custom arrayed genetic screen coupled to the fluorescent reporter 
to delve into the DSB repair landscape in a PARP inhibited background. We uncovered a gene 
cluster that is significantly affected by PARPi and regulates a key step during end-resection, 
suggesting potentially new interactions of PARP1 with DDR. Besides, we propose PARP 
inhibition as an alternative approach to increase the odds of a successful knock-in, since we 
show that PARP inhibition increases the rates of single-strand template repair to a similar 
extent with other well-known strategies. 
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8.1. PARP inhibition deregulates the DNA repair choice 
At present, little is known about how DDR deficiencies influence the DNA repair choice and 
what is the interplay of the repair pathways during this process. Therefore, we used an arrayed 
genetic screen to evaluate the behavior of 417 components of DDR on DNA repair choice upon 
PARP inhibition (Figure 33 A). 
We delivered the library with the solid-phase transfection approach, and three days later we 
transfected the gRNA targeting the eGFP sequence and supplemented the cell culture medium 
with 100 nM of Niraparib. Three days later, we assessed the eGFP and mCherry ratios by high-
throughput flow cytometry. As anticipated from previous experiments, PARP inhibition 
reduced the frequency of small InDels and at the same time increased the frequency of large 
deletions (Figure 33 B,C).  
Similar to the previous analysis, we calculated Z scores of all three populations, but this time 
based on the mean difference (ΔΤ) of the treated to the untreated sample and plotted their effect 
on a scatter plot (Figure 33 D). We removed 13 genes whose KO resulted in a dramatic 
decrease in viability after six days from the subsequent analyses. Among 404 genes after this 
initial filtering step, we formed clusters based on the three populations applying a Mclust 
clustering method. Finally, we estimated the optimal number of clusters to be 8, and then we 
performed pathway enrichment analysis on these 8 clusters. In order to identify the most 
influenced genes of PARP inhibition, we used a standard outlier diagnostic tool (Cook’s 
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distance) for each of the 404 genes. Overall, we identified 30 genes that were recognized as 
outliers and showed a strong influence in their phenotype by PARP inhibition (Figure 33 E). 
 
Figure 33: The impact of PARP inhibition on DNA repair choice. (A) Workflow schematic of the CRISPR/gRNA 
genetic screen. In total, 417 genes are targeted with two different gRNA sequences. HEK293CAT-R cells are induced 
with doxycycline (1 μg/ml) and then transfected with the solid-phase methodology in pre-coated 96-well plates to 
deliver the gRNA arrayed library. At 96 h, the cells are transfected with the gRNA: eGFP and at 7-day analyzed in 
a high-throughput flow cytometer. Data points are averaged, and the Z-score values are calculated per 96-well 
plate. (B) Flow cytometry analysis plot of HEK293CAT-R cells 72 h post-transfection with the synthetic 
crRNA:tracrRNA complex. Comparing the phenotypes between a non-targeting (scrambled) gRNA to a gRNA 
targeting the eGFP sequence and to a gRNA targeting the eGFP sequence in a PARPi background. Numbers 
inside plots indicate percentages of live cells. Axes report relative fluorescence intensity in arbitrary units. (C) Box 
and whiskers plots (min to max) of flow cytometry analysis for the HEK293CAT-R cells that are shown in (B). (D) A 
scatter diagram showing the effect of 404 genes upon Cas9-mediated DSB in a PARPi background. In the x-axis, 
the regulation of small InDels and in the y-axis, the regulation of the large InDels are presented. mClust clustering 
is applied with the “elbow point” to be 8 clusters. Pathway enrichment analysis of the 8 clusters reveals the 
implication of end-resection, end-protection, chromatin organization, and RAD51 related genes. Annotated genes 
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exhibit the most robust phenotype upon Cas9-mediated DSB identified by a standard diagnostic tool. (E) Cook’s 
distance bar plot identifies genes with the most robust phenotype upon PARP inhibition. 
8.2. PARP antagonizes end-resection in double-strand 
break 
Our clustering approach showed that several genes were significantly affected by PARP 
inhibition with the most important processes to be the NER pathway (RPA1, RDC2, PCNA, 
DDB2, CDK7, RBX1), the chromatin organization (TOP2A, PRPF19, DDB1) and the ATR 
signaling pathway (RUVBL1, RFC2, RPA1, XRCC5, PCNA, RPA2, COPS3). In these sets of 
genes, the DNA repair choice was channeled towards the error-free repair by reducing 
simultaneously the frequency of small InDels and large deletions (Figure 34 A). Evidence 
from recent studies describe similar associations of the multifaceted roles of PARP1 in 
chromatin remodeling and explain how PARP1 PARylates histone tails to relax the chromatin 
structure allowing for DNA repair to commence (Ray Chaudhuri and Nussenzweig 2017). In 
addition, PARP inhibition affected also RAD21 that is involved in the regulation of the sister 
chromatin separation with studies to report that PARP inhibition down-regulates the expression 
levels of end-resection components that are also implicated in similar steps such as BRCA1 
and RAD51 (Hegan et al. 2010; Schultz et al. 2003). Therefore, we conclude that the inhibition 
of PARP1 affects mostly genes that are associated with end-resection pathways. 
Furthermore, we identified a gene cluster that is significantly affected by PARPi and increased 
the frequency of small InDels by reducing the levels of end-resection. This cluster is enriched 
in genes responsible for the BARD1 signaling events like the PRBP8, BARD1, and UBE2T 
genes that are interacting with EXO1, a 5’ to 3’ exodeoxyribonuclease, to resolve D-loop 
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structures that are formed during the end-resection repair (Figure 34 A). A recent study 
described how PARP1 blocks EXO1 (Caron et al. 2019) supporting our observations that 
PARP1 probably antagonizes end-resection based mechanisms in several steps. 
 
Figure 34: Identifying novel PARP interactions. Data presented in (A) are a cluster of genes based on relevant 
pathways. Values are normalized to control gRNA: eGFP. (B) A functional network of the most significant genes 
builds in StringDB. (C) Box and whiskers plots (min to max) showing the effect of TONSL-MMS22L complex to 
DSB choice. (D) Box and whiskers plots (min to max) showing the single-strand template repair efficiency in WT 
and several genetic backgrounds. 
The most significant genes that are affected by PARPi create a functional network once 
analyzed with StringDB (Figure 34 B). The DNA repair was highlighted as the primary 
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process, and the nucleus was the cellular place where those interactions take place. The 
TONSL-MMS22L complex stands out with no immediate functional associations to the rest of 
the 28 genes. This complex reduced the frequency of both small InDels and large deletions 
with the simultaneous increase of the error-free repair (Figure 34 C). It appears that PARP 
inhibition regulates its activity since its effect is further enhanced upon inhibition. It is reported 
that this complex stimulates the recombination dependent repair of stalled or collapsed 
replication forks (Duro et al. 2010; Piwko et al. 2016) by promoting HR, and consequently it 
may act by mediating the assembly of RAD51 filaments on ssDNA. Interestingly when we 
targeted RAD51, and the TONSL-MMS22L complex we observed a moderate increase in the 
knock-in efficiency on average 2.9% (±0.4). Collectively from our observations, we suggest 
that PARP1 might antagonizes end-resection based repair mechanisms in more steps than 
already has been described and potentially it interacts with the TONSL-MMS22L complex to 
regulate RAD51 filament formation. 
Furthermore, we wondered whether PARP inhibition influences knock-in efficiency. 
Therefore, we quantified its contribution and compared it with other known strategies that 
enhance knock-in efficiencies, such as the use of a DNA-PKcs inhibitor (M3814) or the use of 
the commercially available HDR enhancer compound (Figure 34 D). Our data showed that 
PARP inhibition increased the knock-in efficiency by 3.9% (±0.7), whereas DNA-PKcs 
inhibition by 3.7% (±0.5) and HDR by 2.8% (±0.2). In summary, we propose that PARP 
inhibition can be considered as an alternative approach to increase the odds of a successful 
knock-in. 
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8.3. A proposed role of PARP in double-strand break 
The current literature suggests that PARP1/2 are one of the first responders to a double-strand 
break (Caron et al. 2019) and perhaps their influence in the choice of DSB repair is more 
significant than already presumed. PARP1/2 facilitates the recruitment of Ku70 to the DSB as 
well as the MRE11 nuclease (Caron et al. 2019). This dual character of PARP1/2 makes it a 
versatile molecule that promotes c-NHEJ but also activates limited end-resection, a step that is 
vital for alt-EJ (Chen et al. 2019; Muthurajan et al. 2014; Wray et al. 2013). In the meantime, 
it is reported that PARP1/2 blocks EXO1 (Caron et al. 2019) supporting the idea that PARP1/2 
are antagonizing extended end-resection during DSB, possibly to favor limited end-resection 
by promoting alt-EJ.  
Here we suggest that PARP1/2 interacts with another step of extended end-resection, the 
RAD51 filament formation (Figure 35). It has been shown that inhibition of PARP1 
downregulates BRCA1 and RAD51 pathway (Hegan et al. 2010), but the exact mechanism of 
downregulation is still missing. We suggest that the TONSL-MMS22L complex is interacting 
with PARP1 to regulate the RAD51 filament formation step. Functional studies have already 
shown that the TONSL-MMSS2L complex promotes RAD51 dependent HR (Duro et al. 2010; 
Piwko et al. 2016) but not in the context of PARP inhibition. We suggest that loss of RAD51 
in a PARP1 deficient background restores the error-free phenotype implying a further 
association of PARP1 to Rad51 filament formation. 
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Figure 35: A proposed role of PARP1 in DSB repair choice. PARP is a protein that interacts in multiple steps 
during the DNA repair process. Recent studies have placed PARP as one of the first responders to a DSB break 
site, dictating the length of resection by blocking EXO1 and recruiting MRE1. Our data suggest that PARP is also 
involved in another process relevant to HR, which is the RAD51 filament formation. We hypothesize that PARP is 
regulating the TONSL-MMS22L complex that also controls the Rad51 loading to the single-stranded DNA.
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Chapter 9 
Discussion  
CAT-R reporter assay 
The purpose of this Ph.D. thesis is to develop a tool to track and quantify the DNA double-
strand break (DSB) repair process. Therefore, we established CAT-R, as an in vitro dual 
fluorescent reporter assay to interrogate the functions of several DSB repair components.  
CAT-R allows for the simultaneous measurement of end-protection and end-resection based 
DSB repair upon a single DSB. We show that CAT-R reporter can be utilized as a high-
throughput tool that can be coupled to chemical and/or genetic screens in different cell lines.  
Over the past decades, several DNA reporter assays have been using I-SceI endonuclease as a 
tool to induce DSBs. The main drawback of this approach is the relatively low cutting 
efficiency of I-SceI and the small number of accessible loci for this endonuclease. In addition, 
the I-SceI endonuclease generates DSB ends with 4 nucleotides (nt) 3’ cohesive overhangs, 
therefore the DNA repair choice is biased to end-resection based mechanisms. We chose to 
combine CAT-R with CRISPR/Cas9 system and induce a high occurrence of DSB phenotype. 
CRISPR is currently the most cutting-edge tool to generate DSBs. Among its advantages is the 
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specificity, adaptability and cutting efficiency that the Cas9 endonuclease exhibits once 
compared to other genome editing tools. Cas9 endonuclease cleaves the DNA three base pairs 
upstream of the PAM site, resulting in a blunt‐end cleavage of DNA, which mimics a natural 
occurring DSB. However, due to the continuous cutting efforts of the Cas9 endonuclease, we 
assume that the repair of a Cas9-mediated DSBs may not be representative of a naturally 
occurring DSBs. In a recent study (Brinkman et al. 2018) a similar assumption is described, 
where the cut and repair process of Cas9 endonuclease is investigated. Brinkman et. al 
concluded that when a target site has acquired an InDel, only then Cas9 can no longer recognize 
the target site.  
Furthermore, due to the high efficiency of DSBs that are introduced by the CRISPR/Cas9 
system, we can simultaneously assess the frequency of small InDels and large deletions with 
an unprecedented resolution. We integrated CAT-R in two non-cancerous cell lines with intact 
DNA repair pathways and observed similar frequencies in the formation of small InDels and 
large deletions. Some of these occurrences are potentially governed by the cell cycle since end-
resection mediated repair primarily occurs in S/G2 phases of the cell cycle, whereas c-NHEJ 
is active throughout the cell cycle (Ceccaldi et al. 2016; Khanna and Jackson 2001; Mjelle et 
al. 2015). As far as the formation of larger deletions upon Cas9-mediated breaks the frequency 
of repair by end-resection may not be uncommon. Our results are consistent with a current 
study describing that more than 20% of larger deletions ranging from 250 bps to 6 kbs can 
occur in a haploid cancer cell lines (Kosicki et al. 2018). 
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DNA repair deficiencies influence CAT-R 
While in general the occurrence of the two error-prone populations (small InDels and large 
deletions) is approximately balanced, this can be altered by channeling the repair of the DSBs 
to either end-protection or end-resection based mechanisms. This occurs because these two 
major pathways are competing for the repair of the DSBs. For this reason, blocking end-
protection mediated repair by knocking out critical components such as DNA-PK and XRCC4, 
increased the frequency of large deletions that are presumably products of end-resection. In 
this case, since the ends of the DSBs cannot be processed by c-NHEJ, they are forced to be 
resected thus are more prone to give rise to larger deletions (Ceccaldi et al. 2016). On the 
contrary, when the critical components of resection mechanisms are inhibited such as BRCA1 
or FA components, the rate of small InDels increases probably due to an increased availability 
of end-protection proteins to seal the DNA ends (Barazas et al. 2018; Pilié et al. 2019). Given 
that such genetic differences can affect the reporter readout so dramatically, we investigated in 
a pilot RNAi screen how PRKDC and PARP1 KO impacts the DNA repair choice. We showed 
that in PARP1 deficient background genes that are important in resection are mostly affected 
and that additional loss of RAD51 can increase the error-free repair. Furthermore, we 
confirmed that deficiencies in PRKDC and PARP1 genes reduce the frequency of small InDels 
by alternative types of repair and showcased that PARP1 requires but is not dependent upon 
microhomologies. In the future, it would be interesting to integrate CAT-R in different cancer 
cell lines with genetic deficiencies in DDR and measure their differences in generating small 
InDels versus large deletions. 
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A platform to screen small pharmacological compounds 
We also demonstrated that due to the high efficiency of DSB induction, CAT-R could be used 
as a platform to screen small-pharmacological compounds to measure their pharmacodynamic 
properties in cell lines. Inhibiting major components of DDR emerged as a therapeutic strategy 
since it provides opportunities for exploitation of complementary DDR pathways on which the 
cancer cells rely on (Curtin 2012; Wright et al. 2017). Understanding a kinase inhibitor’s 
cellular target profile has implications for the correct evaluation of its biological effects in 
DNA repair choice, as this can assist in dissecting the wiring maps of the targeted signaling 
networks (Barakat, Gajewski, and Tuszynski 2012; Curtin 2013; Evers, Helleday, and Jonkers 
2010; Robert et al. 2015). For instance, inhibitors against classical DDR kinases such as  
DNA-PK, ATM, and ATR entered phase I/II clinical trials either as inhibitors for monotherapy 
or in combination with radio- or chemotherapy (Blackford and Jackson 2017; Glorieux, Dok, 
and Nuyts 2017; Klaeger et al. 2017) due to the increased vulnerabilities of tumors cells to 
heightened DNA damage or replication stress (Dietlein, Thelen, and Reinhardt 2014; Pearl et 
al. 2015; Velic et al. 2015).  
With CAT-R, we compared the in vitro drug efficiencies of 24 compounds and assessed the 
qualitative and quantitative impact of these compounds on DNA repair in terms of small InDels 
or large deletion formation. We observed particularly pronounced changes in the CAT-R 
phenotype upon DNA-PK and ATM inhibition and were able to classify different compounds, 
consistent with their reported in vitro potency. 
Cells lacking DNA-PK activity are hypersensitive to ionizing radiation and topoisomerase II 
inhibitors. A comparison among the DNA-PKcs inhibitors on how they tip the balance of DNA 
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repair choice reveals why some inhibitors succeed and some others fail in doing so. The 
NU7026 compound was shown to act in vitro as a radiosensitizer and was also found to 
increase cell sensitivity to topoisomerase II with no intrinsic growth inhibition properties at  
10 μM concentration (Dolman et al. 2015; Nutley et al. 2005). We demonstrate that the 
NU7026 compound has no influence in DNA repair choice at concentrations lower than  
500 nΜ comparing to other potent inhibitors that reach their maximum efficiency in these 
conditions. Another compound that we evaluated was the NU7441. In a recent publication, it 
has been reported that 1 μM of NU7441 is enough to increase cell sensitivity to topoisomerase 
II, doxorubicin as well as IR (Harnor et al. 2017). Even if NU7441 is reported to be selective 
to DNA-PKcs (Chen et al. 2005), still it is suggested that its pharmacokinetic properties can be 
improved (Tavecchio et al. 2012; Zhao et al. 2006). Our data showed that NU7441 can 
influence the DNA repair choice at concentrations around 500 nM but still its efficacy is outrun 
by other more potent inhibitors. The DNA-PKcs inhibitors that yielded the most robust 
phenotypes are M3814 and KU-60019. Both compounds show a stable phenotype at 
concentrations of around 50–500 nM with no intrinsic growth inhibition properties. Of note, 
M3814 entered phase I clinical development in December 2014 (NCT02316197) for use in 
patients with solid tumors who had DNA repair deficiencies, and in patients with chronic 
lymphocytic leukemia. Subsequently, it entered phase I trials in July 2015 (NCT02516813) in 
combination with DNA damaging modalities such as radio-chemotherapy and radiation. 
Disclosure of results by Merck in 2016, indicated that M3814 is active in a preclinical setting, 
exhibiting efficacy in all mouse models of human cancer, in combination with IR (Harnor et 
al. 2017). In addition, when we compared the enzymatic inhibition and the genetic KO of 
PRKDC we observed the same profile in influencing DDR choice by reducing small InDels. 
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We also compared a series of ATM inhibitors to screen for their in-vitro influence in DNA 
repair. On average, ATM inhibition influences the DNA repair choice at concentrations around 
100 nM, with the frequency of large deletions to be favored and the small InDels population 
to be strongly reduced. Consequently, a similar profile with the DNA-PKcs inhibition is 
observed suggesting that ATM inhibition phenocopies DNA-PKcs profile. While we cannot 
exclude off-target effects of these compounds, activation of DNA-PKcs by ATM 
phosphorylation may be a key downstream event that is affected. We were also able to 
highlight the potency of the AZD0156 compound since its influence on DNA repair stands out 
from the other ATM inhibitors at a concentration as low as 1 nM. Furthermore, by comparing 
the enzymatic inhibition and the loss of absence of ATM we observed a different profile since 
in the case of the genetic KO the error-free repair was reduced due to either reduction of HDR 
or error-free NHEJ. An observation that potentially can be explained by the requirement of the 
functional ATM protein to phosphorylate BRCA1 protein that regulates the frequency of the 
error-free repair. 
The next class of compounds we compared was the ATR inhibitors, with some of them to be 
reported to enhance the cytotoxic effects upon radiation (Dillon et al. 2017; Vendetti et al. 
2015, 2018). The analysis of ATR inhibitors revealed that DNA repair is driven to end-
protection pathways upon ATR inhibition. The M4344 compound exhibits the highest potency 
by increasing the frequency of small InDels at low concentrations (< 20 nM). It is worth 
mentioning that all ATR inhibitors showed severe cytotoxic events at concentrations higher 
than 100 nM. 
Another class of inhibitors that we tested was against HDAC. HDAC inhibitors promote the 
acetylation of histones allowing for DNA repair machinery to have better access to the relaxed 
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chromatin. However, and in contrast to what was expected, HDAC inhibition with several 
different pan-spectrum compounds, favors end-protection mechanisms with a substantial 
increase in the frequency of small InDels. To better understand the causal of this action, we 
examined the effect of two potent HDAC inhibitors on the cell cycle. Both compounds 
increased the time cells spent in G1 phase and probably this is enough to explain the increase 
in the formation of small InDels. Thus, the phenotype of HDACi is mostly attributed to the 
cell cycle stalling rather than to DDR manipulation. 
The last class of inhibitors we compared was PARP inhibitors. Targeting PARP1 has been 
extensively studied in recent years to exploit the concept of synthetic lethality (Wright et al. 
2017). For this reason, understanding the profiles of these inhibitors may have important 
implications for the correct evaluation of their biological effects in DNA repair choice, and 
their effects on the cells (Barakat et al. 2012; Curtin 2013; Evers et al. 2010; Robert et al. 
2015). We demonstrate that CAT-R can even detect differences in PARP-trapping activity and 
can be used as a screening platform for a rapid in vitro assessment of DDR compound 
efficiencies. PARP inhibition affects the formation of small InDels, agreeing well with the fact 
that in the presence of PARP, the DSBs are repaired by the alternative EJ pathway. Our system 
classifies the compounds based on their efficacy at the same order as the current literature does. 
Interestingly, when we tested veliparib, iniparib and INO-1001, a group of compounds that are 
among the first PARP inhibitors that were later shown not to possess any PARP-trapping 
activity, none of these three compounds exhibited any prominent effect in the repair of Cas9-
mediated DSBs. This indicates that our system potentially allows the detection of even minor 
changes in DSB repair choice. 
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In the case of PARP1, the genetic KO and the chemical inhibition may be expected to result in 
different phenotypes. However, the effects that we observed with CAT-R are very similar. The 
genetic KO may affect only alt-EJ, thus result in a 5–10% reduction in the small InDels, 
whereas the PARP trapping (inhibition) may affect downstream components of the DSB repair 
that are responsible for end-resection and result in the same phenotype as the genetic KO of 
PARP1. 
The discovery of additional, more potent and selective compounds is desirable. We 
demonstrate that CAT-R can be used as a platform to provide further information on DDR 
kinase or PARP inhibitor drug discovery, serving as a tool to identify more selective inhibitors. 
We also provided a machine learning-based tool to help classify the unknown compounds in  
HEK293CAT-R cells, though we note that the model should be reapplied to additional cell lines 
in order to adapt to the responses in each cell line. 
CRISPR/Cas9 arrayed genetic screen 
A large number of published studies have utilized CRISPR/Cas9 technology for screening 
purposes (Agrotis and Ketteler 2015). CRISPR libraries enable reverse genetic screens with a 
much broader utility in terms of phenotypic readout. With the use of an arrayed genetic library, 
it is possible to explore complex phenotypes that arise from distinct cell perturbations in 
parallel. While the experimental conditions vary between screens, there are at least five crucial 
steps to be considered in an arrayed screen: (1) Preparation of cells; (2) Delivery of the library; 
(3) Phenotype acquisition; (4) Analysis; (5) Hit validation.  
Using the CAT-R, we performed a genetic screen, measuring the effect of knocking out DDR 
genes on the derived populations. Overall, in our screen, loss of c-NHEJ components decreases 
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the rate of small InDels formation, whereas loss of FA pathway components increases the 
number of small InDels and reduces large deletions. Consistently, FA components have been 
recently shown to be required for Cas9-mediated single-strand template repair (SSTR) but not 
for c-NHEJ (Richardson et al. 2018). In addition to the known components of end protection 
and end resection, we revealed components of NER to be necessary for the homology-directed 
repair. We tested this hypothesis by integrating a ssODN based donor template and measuring 
the GFP to BFP conversion, thus assessing the rate of SSTR. Though technically more 
challenging and the frequency of SSTR events are rather low, this conversion allowed us to 
measure the rate of recombination events, together with error-prone repair. We show that in 
the absence of crucial NER genes, the rate of SSTR events is increased. While Cas9 cleaves 
the DNA, the gRNA sequence is bound to the antisense strand as an RNA:DNA hybrid and a 
5’ to 3’ flap is generated at the non-targeted/ sense sequence (Janssen et al. 2019), (Richardson, 
Ray, Dewitt, et al. 2016). Generally, 5’ to 3’ flaps can be removed by the NER mechanism. 
Here, we show that in the absence of these NER genes, most likely the 5’ to 3’ flap cannot be 
removed efficiently increasing the chances of a successful KI via SSTA/HDR. These results 
may have implications for SSTR mediated knock-ins since HDR based genome editing has 
several potential applications such as correction of disease-causing mutations. 
In most cases, since c-NHEJ is more available in the cells, the DSBs are much more commonly 
repaired in an error-prone fashion; thus, strategies to increase the HR mediated repair are 
becoming more attractive. So far,  inhibition of DNA-PK was shown to increase the rate of 
HDR by decreasing the accessibility of the c-NHEJ components to the site of repair (Liu et al. 
2019). Here we provide an alternative approach to increase the rate of knock-ins. It will be 
interesting to see if these effects we observe with the NER deficient cells can be uncoupled 
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from the cell cycle, thus allowing cells that are slow dividing or non-cycling to be edited as 
well.  
Based on the current literature of Cas9-mediated DSB, we propose a mechanism that is derived 
from our genetic screen data. Once Cas9 is bound to its sequence, it undergoes its 
conformational changes and cleaves the loci leaving either as blunt or a sticky end, and it seems 
that the proximal (downstream) to PAM site DNA sequence is left to the end-protection 
mechanism. The distal (upstream) to PAM site DNA sequence is still bound to Cas9 with an 
RNA: DNA hybrid link. Either end-protection machinery will act by holding the strands 
together and favor a quick ligation via c-NHEJ or alt-EJ that will most likely lead to an 
erroneous repair that signals for the formation of small InDels, or a 5’to 3’ flap will be created 
where end-resection machinery will take over. End-resection will either resect the 5’ to 3’ flap 
until a homology is found and this will be repaired with SSA and will lead to large deletions, 
or the existence of 5’ to 3’ will favor the SSTA/HDR with a ssODN donor template.  
Identifying novel PARP interactions 
The impact of the genetic background in DNA repair choice is mostly uninvestigated, with 
several literature data to suggest that PARP1 antagonizes end-resection based mechanism. 
Therefore, we used CAT-R to identify novel PARP1 interactions within DDR. We combined 
the custom arrayed genetic screen with PARP inhibition and were able to identify the 30 most 
altered genes in terms of DSB choice. This approach helped us to uncover a gene cluster that 
controls a key step during RAD51 filament formation, suggesting that PARP1 potentially 
regulates end-resection in more steps, than what was recently being reported. Besides, we show 
that loss of PARP1, as well as inhibition of PARP, deregulates the DNA repair choice in several 
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cases mostly in end-resection related genes to favor limited end-resection and channel the 
repair to alt-EJ or c-NHEJ. Further work needs to be done to understand the precise mechanism 
of how PARP1 regulates end-resection.  
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Chapter 10  
Material & Methods  
Cell line engineering 
Generating Cas9 inducible stable cell lines 
The Edit-R inducible lentiviral Cas9 particles (Horizon™ Dharmacon) confer Blasticidin 
resistance in transduced cells. Both cell lines were Blasticidin resistant, therefore, the 
CRISPR/Cas9 system was used to disrupt the Blasticidin sequence. Specific gRNAs targeting 
the Blasticidin sequence were designed and cloned separately into an all-in-one-vector 
(LentiCRISPR_v2) that expresses both Cas9 endonuclease and the gRNA sequence. After 
transfection and monoclonal cell line expansion, cells were divided into two 96-well plates and 
Blasticidin was supplemented into the culture medium of one of the two 96-well plates to 
determine the number of Blasticidin sensitive clones. Seven days after selection, 90% of the 
clones were Blasticidin sensitive at concentrations as low as 1 μg/ml.  
To generate Cas9 nuclease-expressing cells, the Edit-R™ inducible lentiviral particles 
(Horizon™ Dharmacon) were used according to the manufacturer’s protocol. Cells were 
seeded in a 24-well plate and incubated overnight. The next day the transduction medium was 
prepared to have a MOI=0.3 and the cell culture medium was replenished containing the 
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lentiviral particles. Cells were incubated for 24 h, and then the cell culture medium was 
replaced with the appropriate amount of blasticidin. The transduced cells were selected in the 
presence of 1 μg/ml blasticidin for seven days and the expression of Cas9 was controlled by a 
doxycycline-inducible promoter. 
Generating CAT-R stable cell lines 
The FLP recombinase methodology was used to integrate the reporter as a single stable copy 
into the cell lines of interest. The user’s protocol, (Flp-In™, Invitrogen™), was followed as 
described in the manual. Briefly, general molecular biology techniques such as DNA ligation, 
E. coli transformation, restriction enzyme analysis, and DNA sequencing were applied to clone 
the fluorescent reporter into the constitutively (pcDNA™ 5/FRT) and inducible (pcDNA™ 
5/FRT/TO) expression vectors. Specifically, BamH I & Xho I restriction sites were used to 
ligating the gene of interest to both vectors. The vectors contain the hygromycin resistance 
gene for selection of the transfectants with the antibiotic hygromycin B. To accommodate a 
new antibiotic selection gene for future experiments, the pcDNA™ 5/FRT/TO vector was 
modified. Therefore, the hygromycin resistance gene was replaced by the neomycin resistance 
gene and the pcDNA™ 5/FRT/TO/Neomycin was generated. 
Stable CAT-R expressing cell lines were generated with the Flp-In™ system. The 
pcDNA5™/FRT or the pcDNA™5/FRT/TO construct along with the pOG44 expression 
plasmid were co-transfected to the model cell lines. The transfected cells were selected in the 
presence of 500 μg/μl of hygromycin or neomycin for 4 days. In addition, cells with strong 
eGFP (488-530/30) and mCherry (561-610/20) signals were sorted using FACSAria I cell 
sorter (BD Biosciences) to enrich cells harboring the reporter. 
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Generating cell lines with deficient background 
For each gene of interest one gRNA was used to transfect the model cell lines with the use of 
synthetic gRNA oligonucleotides. Three days post-transfection, monoclonal cell lines were 
generated by limiting dilution and once fully-grown several clones were selected for validation 
either with Western blotting or with Immunofluorescence. 
Table 3: Summary of the engineered cell lines with their respective genetic background 
Nr. Cell line Genetic background 
1. HEK293CAT-R Wild type 
2. HEK293CAT-R PRKDC-/- 
3. HEK293CAT-R XRCC4-/- 
4. HEK293CAT-R ATM-/- 
5. HEK293CAT-R PARP1-/- 
6. HEK293CAT-R ERCC3-/- 
7. HEK293CAT-R ERCC8-/- 
8. HEK293CAT-R XPC-/- 
9. HEK293CAT-R TP53-/- 
10. RPE-1CAT-R Wild type 
11. RPE-1CAT-R TP53-/- 
12. RPE-1CAT-R ATM-/- 
 
Cell culture 
Transformed human embryonic kidney (Flp-In™ HEK293, Life technologies) and hTERT-
immortalized retinal pigment epithelial (hTERT T-Rex™ RPE-1, a kind gift from Jonathon 
Pines) mammalian cell lines were used as model systems. HEK293 cells were cultured in 
Dulbecco's Modified Eagle Medium, high glucose supplement (DMEM/GlutaMAX™, Life 
Technologies) containing 10% FBS (Thermo Scientific), 1% Gibco® Antibiotic-Antimycotic. 
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RPE-1 cells were cultured in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 high 
glucose supplement (DMEM/F12 GlutaMAX™, Life technologies) containing 10% FBS 
(Thermo Scientific), 1% Gibco® Antibiotic-Antimycotic. All cell lines were cultured at 37oC 
and 5% CO2. For the induction of the reporter and the Cas9 endonuclease, culture media was 
supplemented with 1 μg/ml Doxycycline for 24 hours. 
Liquid phase transfection of siRNA 
Cells were seeded (20.000 HEK293, 8.000 RPE-1 cells per 96-well) on 96-well plates (Orange 
Scientific). 24 h later, cells were 60 - 80% confluent for transfection. The Silencer® GFP 
(eGFP) siRNA (Invitrogen™) was used as a positive control for lipofection. 
Lipofectamine™RNAiMAX was used as a transfection reagent, and the general instructions 
for a 96-well plate transfection were followed. The siRNA was combined with 
Lipofectamine™RNAiMA in Opti-MEM® Medium to a final concentration of 1 pmol. 
Liquid phase transfection of synthetic gRNA oligonucleotides: 
Cells were seeded (20.000 HEK293, 8.000 RPE-1 cells per 96-well) on 96-well plates (Orange 
Scientific), and culture media were supplemented with 1 μg/ml Doxycycline. After 24 hrs, 
cells were 60 – 80% confluent for transfection. The Alt-R™ CRISPR crRNA and tracrRNA 
(IDT) were used to form the guide RNA complex (gRNA). Each RNA oligo (Alt-R™ 
CRISPR-Cas9 crRNA, tracrRNA) was resuspended in nuclease-free IDTE, pH 7.5 (1X TE 
solution) to a final concentration of 100 μM. The two RNA oligos were mixed at equimolar 
concentrations to create a final complex concentration of 3 μM. The gRNA complex was 
heated at 95oC for 5 min and then allowed to cool to room temperature (15–25oC). 
Lipofectamine™ RNAiMAX transfection reagent was used according to the user manual. The 
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gRNA complex was combined with Lipofectamine™RNAiMAX in a ratio of 2:1 in Opti-
MEM® Medium to a final concentration of 30 nM. 
Table 4: Selected gRNA designs targeting the eGFP sequence. 
Name Target sequence (5’ → 3’) Nucleotide position* Orientation 
gRNA1 GGGCGAGGAGCTGTTCACCG 12 - 31 Sense 
gRNA2 GAGCTGGACGGCGACGTAAA 52 - 71 Sense 
gRNA3 GGCCACAAGTTCAGCGTGTC 73 - 92 Sense 
gRNA4 GGAGCGCACCATCTTCTTCA 285 - 304 Sense 
gRNA5 GAAGTTCGAGGGCGACACCC 339 - 358 Sense 
gRNA6 GGTGAACCGCATCGAGCTGA 360 - 379 Sense 
* Nucleotide position is determined by the beginning of eGFP sequence 
Solid-phase transfection of synthetic gRNA complexes 
For experiments using a solid-phase transfection platform, we used flat bottom white 96 well 
plates (Costar®Assay plate, 3903) and prepared mixtures that are enough for 9 wells of a 96-
well plate. For each reaction to achieve 2.5 pmol RNA complexes in each coated well, 3 μl 
Opti-MEM/sucrose solution (1.37% w/v) was mixed with 1.75 μl Lipofectamine™2000 
(Invitrogen, 11668027). To this mix, 6.75 μl of 3.3 μM crRNA: tracrRNA mixture was added, 
and the final transfection mix was incubated for 20 mins at room temperature. After incubation, 
7 μl of gelatin (0.2% w/v in H20) was added and mixed. The final mixture was diluted in RNA 
and DNase free water 1:25 amounting to a total of 450 μl of diluted transfection mixes. From 
this mix, we plated 50 μl to each well of a 96 well plate. Plates were filled in triplicates and 
lyophilized using a MiVac vacuum centrifuge, accommodating multi-well plates. 
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Twenty-four hours before transfection, the culture media was supplemented with 1 μg/ml 
Doxycycline. Cells on day of seeding need to be 20 – 30% confluent and were seeded on a pre-
coated flat bottom, 96-well plate (Costar®Assay plate, Corning) (6.000 HEK293 and 3.000 
RPE-1 per 96-well. 
Cell compound treatment 
Twenty-four small pharmacological inhibitors were selected to target vital DDR proteins. The 
compounds were stored as 1 mM stocks in DMSO and bought from Selleckchem or were 
kindly provided (M3814, M3541, M4344 and M6620) by Dr. Frank Zenke at Merck KGaA, 
Darmstadt, Germany. Cells were seeded (20.000 HEK293, 8.000 RPE-1 cells per 96-well) on 
the U-bottom 96-well plate (Orange Scientific), and culture media was supplemented with 1 
μg/ml Doxycycline. The day after, cells were transfected with gRNA: eGFP and incubated 
with the inhibitor compounds for three days. Then they were analyzed in a high-throughput 
FACS LSR Fortessa™ analyzer (BD Biosciences). 
Cell viability assay 
CellTiter-Glo® (Promega) was used to determine cell viability, according to the 
manufacturer’s protocol. Cells were seeded (6.000 HEK293, 3.000 RPE-1 cells per 96-well) 
on a 96-well white plate with a clear flat bottom (Costart®Assay plate, Corning) and cultured 
for three days in the presence of specific inhibitor. The GloMax®-Multi detection system 
(Promega) was used as a luminometer to quantify the presence of ATP when metabolically 
active cells exist. 
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Cell cycle analysis 
Click-iT™ EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit (ThermoFisher) was used as 
an assay for analyzing DNA replication in proliferating cells. The Click-iT® EdU protocol was 
followed. On the day of analysis, cells were labeled with 10 μM of EdU for 2 h, following 
several washing steps during fixation and permeabilization. The Click-iT® reaction mixture 
was prepared according to the manufacturer’s protocol, and the reaction mixture was left for 
incubation for 30 minutes at room temperature protected from light. Cells were stained for 
DNA content with the FxCycle™ Violet in 1:1000 dilution and left for 30 minutes of 
incubation. The samples were analyzed by flow cytometry with the use of a FACSAria I cell 
sorter (BD Biosciences). 
CRISPR/Cas9 gRNA library 
An arrayed gRNA library is synthesized on 96 well plates targeting a total of 417 genes (IDT). 
For each gene, 2 individual gRNAs were used. On each plate, we used four positives 
(POLR2A), and six negatives (Scrambled, non-targeting gRNA) controls to evaluate the solid-
phase transfection. On the first day, the culture media was supplemented with 1 μg/ml 
Doxycycline to induce the Cas9 expression. On day 2, cells were 60-80% confluent and 
actively dividing. They were seeded in pre-coated plates containing the gRNA library 
complexes. Three days post-transfection, the gRNA: eGFP was transfected, and three days 
afterward, the eGFP and mCherry ratios were assessed by high throughput flow cytometry. 
Genomic DNA extraction 
Cells were collected 24 to 72 h after transfection to a 1.5 ml tube. The genomic DNA was 
isolated according to the manufacturer’s protocol using the DNeasy Blood & Tissue Kit 
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(Qiagen). In brief, cultured cells were pelleted and resuspended in 200 μl PBS with 20 μl of 
proteinase K. Afterward, 200 μl of Buffer AL was added to the sample, mixed thoroughly, and 
left to incubate at 56oC for 10 min. Then 200 μl of ethanol (96-100%) was used and subsequent 
washing steps with Buffer AW1 and Buffer AW2 followed. The final elution step was 
performed with 50 μl of nuclease-free water. The DNA purity and concentration were 
measured using a NanoDrop™ spectrophotometer.  Typically, A260/280 values greater than 
1.8 are suitable for analysis. 
Cleavage detection assay 
The enzyme digest of mispaired dsDNA was performed using the Surveyor® Mutation 
detection kit (IDT) according to the manufacturer’s protocol. The PCR amplification of  
100 ng from reference and test samples was completed, using the Q5 Hot Start High-Fidelity 
2X Master Mix (#M0494, New England Biolabs). The thermo-cycling conditions of the 25 μl 
PCR reactions were 98°C for 30 sec, 34 cycles of 98°C for 5 s, 59°C for 10 sec, and 72°C for 
20 sec with a final extension at 72°C for 2 min.  Next, sample and reference DNA are 
hybridized to form heteroduplexes using a thermal cycler according to the manufacturer’s 
protocol. Subsequently, 10 μl from the PCR reaction for each sample was used to set up the 
surveyor nuclease reaction and the mixture was left at 42oC for 60 min of incubation. Finally, 
the analysis of DNA fragments was run in a 1.5% TBE agarose gel electrophoresis and imaged 
with a Gel Doc™ XR+ (Bio-Rad) system.  
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PCR amplification and Next-Generation Sequencing 
For the genome-sequencing assay, DNA was extracted from HEK293 cells using the DNeasy 
Blood & Tissue Kits (Qiagen, Düsseldorf, Germany) as described in the manufacturer’s 
protocol. After quantification (Qubit High sensitivity assay kit) we employed a two-step PCR 
protocol. As suggested in the Illumina protocol for 16S Metagenomic Sequencing Library 
Preparation, the first PCR step is performed to amplify the targeted DNA region. For each 
sample, 1 μg of DNA was used to prepare the initial 388 bps PCR amplicon. The 50 μl PCR 
reactions were set up with the NEBNext® Q5® Hot Start Master Mix (New England BioLabs) 
and the thermo-cycling conditions were 98°C for 3 min, 12 cycles of 98°C for 10 s, 65°C for 
30 sec, and 72°C for 20 sec with a final extension at 72°C for 3 min. To verify the success of 
the PCR, amplification products were electrophoresed on a 2% agarose gel. The second PCR 
step is performed in order to multiplex individual specimens on the same Illumina MiSeq 
flowcell and to add necessary Illumina adapters. In this second step, primer pairs used contain 
the appropriate Illumina adapter allowing amplicons to bind to the flow cell, an 8-nt index 
sequence (Kozich et al. 2013) and the Illumina sequencing primer sequence. 
Next-Generation Sequencing data analysis 
The reads quality control was performed with FastQC and MultiQC tools. BBMap (v. 38.34) 
was used for the alignment because of its accuracy to align reads with long indels. As a 
reference, the targeted eGFP sequence was used. All the downstream analysis was performed 
with custom scripts in R (v. 3.4.4). Indels were considered only if they occurred within 1 
nucleotide of the Cas9 cleavage site. To guarantee the robustness of the frequency’s estimation, 
Material and Methods: Chapter 10     
132 
 
only events (indels with a unique position and length) supported by at least 10 reads were 
considered. 
High-throughput flow cytometry 
Cell populations were gated on a forward (FSC)/side scatter (SSC) plot. Cells are further gated 
on forward-area (FSC-A)/forward-height scatter (FSC-H) plot to determine single cells. Single 
cells are further gated on side-area scatter (SSC-A)/ (405-450/50A) to determine living cells 
based on DAPI staining. Live cells are further gated to determine eGFP (488-530/30-A)/ 
mCherry (561-610/20-A) cell populations and evaluated in a ratiometric way the fluorescent 
variations in a FACS LSRFortessa™ mounted on a High Throughput Samples (HTS) (BD 
Biosciences, USA). 
Quantify gene expression 
Western blotting 
Whole-cell lysis extracts of HEK293 and RPE-1 were generated with RIPA buffer (CST – 
9806S) or custom made HGNT lysis buffer. An equal amount of protein (25 μg/ml) was loaded 
to a 7.5% precast polyacrylamide gel (Mini-PROTEAN® TGX™, Bio-Rad). The cell extracts 
were transferred to a nitrocellulose membrane (Trans-Blot® Turbo™, Bio-Rad) or to a PVDF 
membrane using a transfer apparatus according to the manufacturer’s protocols (Bio-Rad). 
After incubation with 10% nonfat milk in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% 
Tween 20) for 30 min, the membrane was washed three times with TBST and incubated with 
antibodies against protein of interest at 4oC for 12 h. Membranes were washed three times and 
incubated with 1:10000 dilution of IRDye 680RD and IRDye 800CW secondary antibodies for 
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2 h. Blots were washed with TBST three times and developed with the Odyssey system for 2 
min (LI-COR Biosciences). 
Table 5: List of protein targets with the respective antibodies used during this study. 
Protein 
target 
Dilution Molecular 
weight (kDa) 
Antibody 
type 
Product 
number 
Company 
Cas9 1:1000 160 kDa Mouse mAb #14697s CST 
TP53 1:1000 53 kDa Mouse mAb #2524S CST 
ATM 1:1000 350 kDa Rabbit mAb #2873S CST 
p-CHK2 1:1000 56 kDa Rabbit mAb #2197s  CST 
XRCC4 1:500 55 kDa Mouse mAb sc-271087 Santa Cruz 
NHEJ1 1:100 27.8 kDa Mouse mAb sc-393844 Santa Cruz 
DNA-PKcs 1:1000 469 kDa Rabbit pAb ab70230 Abcam 
eGFP 1:1000 37.2 kDa Mouse mAb   
GAPDH 1:10000 37 kDa Rabbit mAb #5174s  CST 
α-Tubulin 1:10000 50 kDa Mouse mAb ab67291 Abcam 
Vinculin 1:10000 145 kDa Rabbit mAb #4650s CST 
CST: Cell Signaling Technology 
 
RNA Extraction, cDNA Synthesis, and RT-qPCR 
Total RNA isolation was performed from 106 cells using the RNeasy Plus Mini kit (Qiagen, 
Düsseldorf, Germany). Cells were pelleted and disrupted by adding Buffer RLT that contains 
β-mercaptoethanol (β-ME) to denature active RNases. After homogenizing the lysates by 
vortexing for 1 min, 1 volume of 70% ethanol was added to the mixture. Subsequent washing 
steps, with Buffer RPE, were followed and the elution was performed with 10 μl of nuclease-
free water. The RNA samples were diluted to 250 ng/μl final concentration aliquoted and stored 
in -80oC.  
All RNA samples within an experiment were reverse transcribed at the same time with the 
qScript™ cDNA SuperMix (Quanta Biosciences) using 500 ng of RNA as a template and stored 
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in aliquots at -80 oC. Real-time PCR with Fast SYBR® Green (ThermoFisher) detection was 
performed using a QuantStudio™ 5 Real-Time PCR system (Applied Biosystems™). The 
relative quantification of each sample was performed using the comparative Ct method. The 
acidic ribosomal phosphoprotein P0 gene (36B4) is used as a housekeeping gene. To compare 
the transcript levels between different samples the 2 -Ct method was used (Livak and 
Schmittgen, 2001). First, the difference in the cycle threshold (Ct) values between the 18S gene 
and a target gene were calculated with or without treatment, (ΔCtgene-18S)treated, (ΔCtgene-18S)non-
treated. Then, the difference
 between these values was calculated as follows: ΔCttreated - non-treated = 
(ΔCtgene-18S)treated - (ΔCtgene-18S)non-treated. Finally, to determine the ratio of expression levels in 
the treated sample versus non-treated sample, we used the Qr formula (𝑄𝑟 =
2−𝐶𝑡𝑡𝑟𝑒𝑎𝑡𝑒𝑑−𝑛𝑜𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑). 
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Table 6: RT-PCR primer set 
Gene Orientation Primer sequence (5’ → 3’) 
ATM Fwd ATCTGCTGCCGTCAACTAGAA 
Rev GATCTCGAATCAGGCGCTTAAA 
ATR Fwd GGCCAAAGGCAGTTGTATTGA 
Rev GTGAGTACCCCAAAAATAGCAGG 
BRCA1 Fwd GCTACAGAAACCGTGCCAAA 
Rev TATCCGCTGCTTTGTCCTCA 
BRCA2 Fwd TGGTATGCTGTTAAGGCCCA 
Rev CTGGGGCTTCAAGAGGTGTA 
ERCC5 Fwd GACTTAGCGTCCAGTGACTCC 
Rev GGCAGTTTTGATGGCTTGTCTTT 
ERCC8 Fwd ATGCTGGGGTTTTTGTCCG 
Rev TCTCCGTGTTGACTCTGCTCT 
FANCI Fwd CCACCTTTGGTCTATCAGCTTC 
Rev CAACATCCAATAGCTCGTCACC 
FANCM Fwd AATCTTGGCTCTAAGTGCCAC 
Rev TCTGCCCAATTAGCAGGTTAGTA 
NHEJ1 Fwd ATAATCTCCTTCGCCCATTGTTG 
Rev CCCGTAGAATCAGTGCATCTG 
PARP1 Fwd TGGAAAAGTCCCACACTGGTA 
Rev AAGCTCAGAGAACCCATCCAC 
PARP2 Fwd GCCTTGCTGTTAAAGGGCAAA 
Rev TCCTTCACAATACACATGAGCC 
PARP3 Fwd GCCCTGGGTACAGACTGAG 
Rev CGCTTCTCTGCGGGTATGG 
POLQ Fwd ACTTTTGCTGACCAAGATTTGCT 
Rev ACTCATGCCAACGATTTGCAC 
PRKDC Fwd CTGTGCAACTTCACTAAGTCCA 
Rev CAATCTGAGGACGAATTGCCT 
RAD51B Fwd CACCAGACCCAGCTCCTTTA 
Rev TCTGTTCTGTAAAGGGCGGT 
USP1 Fwd CGTTTCCGGGACCAGAATCC 
Rev CATCGCCGTCCGTTCTCTTC 
XRCC4 Fwd ATGACTGCTGACCGAGATCC 
Rev CTGAAGCCAACCCAGAGAGA 
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Statistical analysis 
Compound analysis and statistical testing 
Results from the reporter are presented as the mean ±standard deviation of independent 
experiments. Each independent experiment entails 3 technical replicates. A t-test was used to 
compare continuous variables between two groups. Box and whiskers plots are used from min 
to max with median value to be annotated and values to be normalized to gRNA: eGFP control. 
Scatter plots are also used with a nonlinear regression fit curve and the values to be normalized 
to gRNA: eGFP control. 
Random forest model – a bioinformatics pipeline 
Starting from the log10 transformed FACS data, for each sample, the 2D kernel density 
estimation was computed, and the resulting plot was converted into a 100 x 100 pixels image 
flatten into a 10000 elements vector. To avoid misleading the modeling process samples that 
showed a phenotype almost equal to the DSB were removed as follows: assuming that equal 
phenotypes come from the same distribution, for each sample the statistical distances from the 
DSB controls within the plate were computed  using the Kolmogorov–Smirnov test and an 
average distance from the DSB controls was calculated. Samples showing an average distance 
equal to or lower than the upper endpoint of the 95% confidence interval of the average 
distance among the DSB controls within the plate were filtered out. Specific drugs no longer 
considered to belong to a specific class were also removed. The data set was split randomly 
into train and test set using an 80/20 ratio and taking the classes proportion of the data unvaried. 
Using the train set, we trained a random forest model with a repeated 5-fold cross-validation 
for the parameter’s optimization and an up-sampling strategy for class balancing. In order to 
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assess the final model, we predicted the classes of the test set. Afterward, we were able to 
produce the confusion matrix and to calculate the performance of the model. The modeling 
was performed in R using the caret and the ranger packages. 
CRISPR/Cas9 gRNA library analysis 
The data from the two replicates were averaged by the gene name. In statistics, Z-score values 
are used to describe a value's relationship to the mean of a group of values based on the standard 
deviations from the mean. Therefore, Z-scores were calculated with the following formula 
𝑍 𝑠𝑐𝑜𝑟𝑒 =  
(𝑉𝑎𝑙𝑢𝑒−𝑚𝑒𝑎𝑛)
𝑆𝐷
, for all three populations per gene based on non-targeting (scrambled) 
controls of each 96-well plate. Genes with a low number of counts (< 1500) were removed 
from the analysis. Among the remaining genes, we formed clusters by the K-Means algorithm, 
taking into consideration all three populations. K-Means is a popular technique for data cluster 
analysis that partitions the input data set into k partitions (clusters) starting with the first group 
of randomly assigned centroids. Once the centroids are stabilized it allocates every data point 
to the nearest cluster. Next, a pathway enrichment analysis was performed to identify pathways 
enriched in the given gene list sets derived from the clustering approach. For this purpose, a 
free online database of biological pathways (Reactome) was used. The website can be used to 
browse pathways and submit data to a suite of data analysis tools. The pathway over-
representation tool was used to present a list of over-represented pathways with a significance 
level of p < 0.05. Next, to identify the most influential genes of a Cas9-mediated DSB, a 
standard outlier diagnostic tool (Cook’s distance) was used. It is commonly used to estimate 
the influence of a data point when performing a least-squares regression analysis. A model 
based on the input of the two populations is built in the concept 𝑦 = 𝑥 ∗ 𝛽 + 𝜀, with ε to be the 
error term. If ε is greater than the cut-off (3 times the mean) then it is considered as an outlier.
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